var title_f34_49_35600="Supracondylar fracture with pucker sign";
var content_f34_49_35600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Supracondylar fracture with pucker sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient had penetration of the spike of the proximal fragment into the subcutaneous tissue. In the anteroposterior view (Panel A), there is a large puckering or defect in the skin where the distal fragment has pulled the skin inward. Laterally (Panel B), there is puckering of the skin (arrow) in the area where the spike has penetrated into the subcutaneous tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35600=[""].join("\n");
var outline_f34_49_35600=null;
var title_f34_49_35601="Cystic fibrosis lung";
var content_f34_49_35601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross pathology of the lung in cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lung specimen from a patient with cystic fibrosis demonstrating grossly purulent secretions in dilated airways.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Claire Langston, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35601=[""].join("\n");
var outline_f34_49_35601=null;
var title_f34_49_35602="Paracocci sequelae";
var content_f34_49_35602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sequelae in paracoccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequelae of paracoccidioidomycosis following treatment. A and B. Microstomia resulting from perioral lesions. C. Tracheal stenosis requiring tracheostomy. D. Chest radiograph demonstrating lung fibrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shikanai-Yasuda, MA, Queiroz Telles Filho, F, Mendes, RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright &copy;2006 Sociedade Brasileira de Medicina Tropical.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35602=[""].join("\n");
var outline_f34_49_35602=null;
var title_f34_49_35603="CDC SSI classification";
var content_f34_49_35603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Cross-section of abdominal wall depicting CDC classifications of surgical site infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection. In: Infection Control and Hospital Epidemiology, CDC 1999; 20:247.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35603=[""].join("\n");
var outline_f34_49_35603=null;
var title_f34_49_35604="Clindamycin (systemic): Patient drug information";
var content_f34_49_35604=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clindamycin (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/46/41704?source=see_link\">",
"     see \"Clindamycin (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/1/8215?source=see_link\">",
"     see \"Clindamycin (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8008032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cleocin HCl&reg;;",
"     </li>",
"     <li>",
"      Cleocin Pediatric&reg;;",
"     </li>",
"     <li>",
"      Cleocin Phosphate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8008033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clindamycin&reg;;",
"     </li>",
"     <li>",
"      Ava-Clindamycin;",
"     </li>",
"     <li>",
"      Clindamycin Injection, USP;",
"     </li>",
"     <li>",
"      Clindamycine;",
"     </li>",
"     <li>",
"      Dalacin&trade; C;",
"     </li>",
"     <li>",
"      Mylan-Clindamycin;",
"     </li>",
"     <li>",
"      PMS-Clindamycin;",
"     </li>",
"     <li>",
"      Riva-Clindamycin;",
"     </li>",
"     <li>",
"      Teva-Clindamycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very loose stools (diarrhea). Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701824",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clindamycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Liver disease or very loose stools called pseudomembranous colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not lie down for at least 30 minutes after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store the shot closely. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11601 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35604=[""].join("\n");
var outline_f34_49_35604=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008032\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008033\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024962\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024964\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024963\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024968\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024969\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024971\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024966\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024967\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024972\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024973\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/46/41704?source=related_link\">",
"      Clindamycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/1/8215?source=related_link\">",
"      Clindamycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/46/5862?source=related_link\">",
"      Clindamycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/21/2389?source=related_link\">",
"      Clindamycin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/21/38229?source=related_link\">",
"      Clindamycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_49_35605="Acrokeratosis verruciformis";
var content_f34_49_35605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acrokeratosis verruciformis of Hopf",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35605=[""].join("\n");
var outline_f34_49_35605=null;
var title_f34_49_35606="Follicular mixed NHL";
var content_f34_49_35606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular lymphoma grade II (follicular mixed lymphoma)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is an intimate admixture of small cleaved cells (centrocytes) and large non-cleaved cells (centroblasts).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35606=[""].join("\n");
var outline_f34_49_35606=null;
var title_f34_49_35607="Disopyramide: Drug information";
var content_f34_49_35607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Disopyramide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/8/1157?source=see_link\">",
"    see \"Disopyramide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/53/30550?source=see_link\">",
"    see \"Disopyramide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norpace&reg;;",
"     </li>",
"     <li>",
"      Norpace&reg; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norpace&reg;;",
"     </li>",
"     <li>",
"      Rythmodan&reg;;",
"     </li>",
"     <li>",
"      Rythmodan&reg;-LA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F161716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class Ia",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F161675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ventricular arrhythmias:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Since newer agents with less toxicity are available, the use of disopyramide for this indication has fallen out of favor. Controlled release formulation not to be used when rapid achievement of disopyramide plasma concentrations is desired. A maximum dose up to 400 mg every 6 hours (immediate release) may be required for patients with severe refractory ventricular tachycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;50 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     An initial loading dose of 200 mg may be administered if rapid onset is required. Maintenance dose: 100 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Controlled release:",
"     </i>",
"     Maintenance dose: 200 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;50 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     An initial loading dose of 300 mg may be administered if rapid onset is required. Maintenance dose: 150 mg every 6 hours. If rapid control is necessary and no response seen within 6 hours of loading dose, may increase maintenance dose to 200 mg every 6 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Controlled release:",
"     </i>",
"     Maintenance dose: 300 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertrophic cardiomyopathy (obstructive physiology) with or without atrial fibrillation (unlabeled use):",
"     </b>",
"     Oral: Initial:",
"     <i>",
"      Controlled release:",
"     </i>",
"     200-250 mg twice daily. If symptoms do not improve, increase by 100 mg/day at 2-week intervals to a maximum daily dose of 600 mg (Gersh, 2011; Sherrid, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F161695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/53/30550?source=see_link\">",
"      see \"Disopyramide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Arrhythmias:",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1 year: 10-30 mg/kg/24 hours in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1-4 years: 10-20 mg/kg/24 hours in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     4-12 years: 10-15 mg/kg/24 hours in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     12-18 years: 6-15 mg/kg/24 hours in 4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F161676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Dose with caution, starting at the lower end of dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F161677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manufacturer recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;40 mL/minute: 100 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-40 mL/minute: 100 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: 100 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: 100 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Controlled release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;40 mL/minute: 200 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;40 mL/minute: Not recommended for use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternative recommendations (Aronoff, 2007):",
"     <i>",
"      Immediate release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: 100-200 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: 100-200 mg every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 100-200 mg every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%) by hemo- or peritoneal methods; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F161678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Manufacturer&rsquo;s recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     100 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Controlled release:",
"     </i>",
"     200 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norpace&reg;: 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, controlled release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norpace&reg; CR: 100 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F161652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not break or chew controlled release capsules. Administer around-the-clock rather than 4 times/day (ie, 12-6-12-6, not 9-1-5-9) to promote less variation in peak and trough serum levels. Should be taken on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F161651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F1076309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alternative agent for the prevention of recurrent symptomatic focal atrial tachycardia (in combination with an AV nodal blocking agent), atrial fibrillation (especially vagally-induced), or atrial flutter (in combination with an AV nodal-blocking agent); obstructive hypertrophic cardiomyopathy (HCM) in combination with ventricular rate-controlling agents (eg, beta blockers or verapamil) to control symptoms of angina or dyspnea who are unresponsive to rate-controlling agents alone; atrial fibrillation in patients with HCM in combination with rate-controlling agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F161724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Disopyramide may be confused with desipramine, dipyridamole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norpace&reg; may be confused with Norpramin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F161714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The most common adverse effects are related to cholinergic blockade. The most serious adverse effects of disopyramide are hypotension and CHF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (32%), constipation (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary hesitancy (14% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: CHF, hypotension, cardiac conduction disturbance, edema, syncope, chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, malaise, dizziness, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash, generalized dermatoses, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol increased, hypokalemia, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dry throat, nausea, abdominal distension, flatulence, abdominal bloating, anorexia, diarrhea, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention, urinary frequency, urinary urgency, impotence (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, muscular pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, dry eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, AV block, cholestatic jaundice, depression, dysuria, creatinine increased, gynecomastia, hepatotoxicity, hypoglycemia, BUN increased, insomnia, new or worsened arrhythmia (proarrhythmic effect), paresthesia, psychotic reaction, respiratory distress, thrombocytopenia, transaminases increased. Rare cases of lupus have been reported (generally in patients previously receiving procainamide), peripheral neuropathy, psychosis, toxic cutaneous blisters.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F161656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to disopyramide or any component of the formulation; cardiogenic shock; pre-existing second- or third-degree heart block (except in patients with a functioning artificial pacemaker); congenital QT syndrome; sick sinus syndrome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F161636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May occur during the initiation of therapy; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects: Watch for proarrhythmic effects; may cause QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and subsequent torsade de pointes; avoid use in patients with diagnosed or suspected congenital long QT syndrome. Monitor and adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrial fibrillation/flutter: Appropriate use: In patients with atrial fibrillation or flutter, block the AV node before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; BPH/urinary retention: Do not use in patients with BPH and/or urinary retention due to significant anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction disturbances: Use with caution in patients with bundle branch block or heart block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Do not use in patients with glaucoma due to significant anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution or avoid in patients with any degree of left ventricular dysfunction or history of HF; may precipitate or exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reduced dosage recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Do not use in patients with myasthenia gravis due to significant anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in renal impairment; reduced dosage recommended. The controlled release form is not recommended for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;40 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wolff-Parkinson-White syndrome: Use with caution in patients with Wolff-Parkinson-White syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Avoid concurrent use with other drugs known to prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval or decrease myocardial contractibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to a risk of developing heart failure (potent negative inotrope) and adverse effects associated with its  potent anticholinergic properties; alternative antiarrhythmic agents preferred (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CAST trial:",
"     <b>",
"      [U.S. Boxed Warning]: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide.",
"     </b>",
"     An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F161711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Risk of QTc prolongation and Torsades de Pointes may be increased; consider alternative therapy when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Disopyramide may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Disopyramide may enhance the arrhythmogenic effect of Lidocaine (Systemic). Disopyramide may increase the serum concentration of Lidocaine (Systemic). Specifically, the unbound/free fraction of lidocaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Disopyramide may enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: May enhance the QTc-prolonging effect of Disopyramide. Management: Consider alternatives to disopyramide in patients with acute lurasidone overdose.  If disopyramide treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May enhance the adverse/toxic effect of Disopyramide. Of particular concern is the potential for profound depression of myocardial contractility.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F161668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Management: Administer at the same time around-the-clock on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease disopyramide levels. Ephedra may worsen arrhythmia. Management: Avoid St John's wort and ephedra.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Disopyramide levels have been reported in human fetal blood. Disopyramide may stimulate contractions in pregnant women. In a case report, disopyramide use in the third trimester resulted in painful uterine contractions after the first dose and hemorrhage after the second dose (Abbi, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F161682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F161659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F161658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (Norpace CR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $246.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $291.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Disopyramide Phosphate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $69.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $81.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Norpace Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $225.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $265.96",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F161645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, blood pressure, urinary retention, CNS anticholinergic effects (confusion, agitation, hallucinations, etc); disopyramide drug level (if available)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F161648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atrial arrhythmias: 2.8-3.2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ventricular arrhythmias 3.3-7.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic concentration: &gt;7 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F161660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dicorantil-F (BR);",
"     </li>",
"     <li>",
"      Dicorynan (ES);",
"     </li>",
"     <li>",
"      Dimodan (MX);",
"     </li>",
"     <li>",
"      Dirytmin (LU, NL, SE);",
"     </li>",
"     <li>",
"      Disocor (PL);",
"     </li>",
"     <li>",
"      Disomet (FI);",
"     </li>",
"     <li>",
"      Durbis (DK, SE);",
"     </li>",
"     <li>",
"      Durbis Retard (NO, SE);",
"     </li>",
"     <li>",
"      Durbis[inj.] (DK);",
"     </li>",
"     <li>",
"      Heartoace (TW);",
"     </li>",
"     <li>",
"      Norpace (BB, CH, DE, DK, HR, IE, IN, KP, MY, PH, SR, TR, TT, ZA);",
"     </li>",
"     <li>",
"      Norpace Retard (HK, PH, ZA);",
"     </li>",
"     <li>",
"      Norpaso (AR);",
"     </li>",
"     <li>",
"      Palpitin (HN, HU, PL);",
"     </li>",
"     <li>",
"      Regubeat (IN);",
"     </li>",
"     <li>",
"      Ritmodan (IT, PT);",
"     </li>",
"     <li>",
"      Ritmoforine (NL);",
"     </li>",
"     <li>",
"      Rythmical (IL);",
"     </li>",
"     <li>",
"      Rythmodan (AE, AT, AU, BE, BH, CY, CZ, EG, FR, GB, GR, IE, IQ, IR, JO, KW, LB, LU, LY, NL, NZ, OM, PL, QA, RU, SA, SY, YE, ZA);",
"     </li>",
"     <li>",
"      Rythmodan Retard (PL, ZA);",
"     </li>",
"     <li>",
"      Rythmodul (DE);",
"     </li>",
"     <li>",
"      Rytmilen (BG, CZ, PL, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F161635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class Ia antiarrhythmic: Decreases myocardial excitability and conduction velocity; reduces disparity in refractory between normal and infarcted myocardium; possesses anticholinergic, peripheral vasoconstrictive, and negative inotropic effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F161655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 0.5-3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release: 1.5-8.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 60% to 83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.8-2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding (concentration dependent): 20% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; N-dealkylation to the active metabolite N-despropyldisopyramide (or mono-N-dealkylated [MND] metabolite) and other inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: 4-10 hours; prolonged with hepatic or renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release: Within 2 hours; Controlled release: 4-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~50% as unchanged drug; ~20% as MND; 10% other metabolites); feces (10% to 15%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(15):1871-909.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/14557344/pubmed\" id=\"14557344\" target=\"_blank\">",
"        14557344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coplen SE, Antman EM, Berlin JA, et al, &ldquo;Efficacy and Safety of Quinidine Therapy for Maintenance of Sinus Rhythm After Cardioversion. A Meta-analysis of Randomized Control Trials,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1990, 82(4):1106-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/2144796/pubmed\" id=\"2144796\" target=\"_blank\">",
"        2144796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crijns HJ, Gosselink AT, and Lie KI, &ldquo;Propafenone versus Disopyramide for Maintenance of Sinus Rhythm After Electrical Cardioversion of Chronic Atrial Fibrillation: A Randomized, Double-blind Study,&rdquo;",
"      <i>",
"       Cardiovasc Drugs Ther",
"      </i>",
"      , 1996, 10(2):145-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/8842506/pubmed\" id=\"8842506\" target=\"_blank\">",
"        8842506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Echt DS, Liebson PR, Mitchell LB, et al, &ldquo;Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(12):781-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/1900101/pubmed\" id=\"1900101\" target=\"_blank\">",
"        1900101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaker GC, Blackshear JL, McBride R, et al, &ldquo;Antiarrhythmic Drug Therapy and Cardiac Mortality in Atrial Fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1992, 20(3):527-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/1512329/pubmed\" id=\"1512329\" target=\"_blank\">",
"        1512329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maron BJ, \"Hypertrophic Cardiomyopathy: A Systematic Review,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(10):1308-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/11886323/pubmed\" id=\"11886323\" target=\"_blank\">",
"        11886323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morganroth J and Goin JE, &ldquo;Quinidine-Related Mortality in the Short-to-Medium Term Treatment of Ventricular Arrhythmias,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 1991, 84(5):1977-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/1834365/pubmed\" id=\"1834365\" target=\"_blank\">",
"        1834365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sherrid MV, Barac I, McKenna WJ, et al, \"Multicenter Study of the Efficacy and Safety of Disopyramide in Obstructive Hypertrophic Cardiomyopathy,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1251-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/15837258/pubmed\" id=\"15837258\" target=\"_blank\">",
"        15837258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/49/35607/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9378 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-FDE34C00CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35607=[""].join("\n");
var outline_f34_49_35607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708704\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161671\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161672\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161716\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161675\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161695\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161676\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161677\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161678\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161647\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161632\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161652\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161651\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1076309\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161724\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161714\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161656\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161636\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161711\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161641\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161668\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161643\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494698\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161682\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161659\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161658\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161645\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161648\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161660\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161635\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161655\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9378\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9378|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/8/1157?source=related_link\">",
"      Disopyramide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/53/30550?source=related_link\">",
"      Disopyramide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_49_35608="Differential diagnosis of fibromyalgia";
var content_f34_49_35608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of fibromyalgia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/49/35608/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/49/35608/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/49/35608/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/49/35608/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/49/35608/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/49/35608/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/49/35608/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal feature of fibromyalgia (FM) is chronic, widespread pain that is not explained by another rheumatic or systemic disorder. Explicit in this definition is the exclusion of other conditions that can present with widespread pain. Thus, although the differential diagnosis of FM may potentially become quite complicated, it should actually be relatively simple [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rather than worrying about every disease that can cause musculoskeletal pain, the clinician should focus on the characteristic features of fibromyalgia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain above and below the waist, which is bilateral and axial for at least three months",
"     </li>",
"     <li>",
"      Somatic complaints including fatigue and sleep, mood, and cognitive disturbance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms are often present in many other diseases. However, these other conditions, such as infection, often either are transient or manifest abnormal physical and laboratory findings. In fibromyalgia, the physical examination, other than tenderness in muscles and soft tissue (tender points), is unrevealing and, laboratory and imaging are unremarkable.",
"   </p>",
"   <p>",
"    Conditions that should be considered in the differential diagnosis of FM include other disorders that may mimic FM or that may occur as comorbid conditions, as well as a collection of common disorders that often overlap with FM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These latter illnesses are common and can present challenges in differential diagnosis. They include myofascial pain syndrome, chronic fatigue syndrome, irritable bowel syndrome, pelvic and bladder pain disorders, and temporomandibular pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/4\">",
"     4",
"    </a>",
"    ]. Like fibromyalgia, each of these conditions is very common and controversial, since there are no objective abnormalities found on the physical, laboratory, or radiologic examinations. As a result, fibromyalgia and these overlapping disorders are often termed &ldquo;functional somatic syndromes.&rdquo;",
"   </p>",
"   <p>",
"    This topic will review the differential diagnosis of fibromyalgia in adults. The clinical manifestations, diagnosis, and treatment of this condition in adults, as well as fibromyalgia in children and adolescents, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/23/2424?source=see_link\">",
"     \"Approach to the patient with myalgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5786?source=see_link\">",
"     \"Treatment of fibromyalgia in adults not responsive to initial therapies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7896?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19350?source=see_link\">",
"     \"Treatment and prognosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1752243\">",
"    <span class=\"h1\">",
"     APPROACH TO THE DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to the differential diagnosis in a patient with complaints suggestive of fibromyalgia is a thorough history and physical examination. Baseline blood tests should be limited to a complete blood count, erythrocyte sedimentation rate (ESR), standard blood chemistries, and thyroid function tests. These tests are all usually normal in patients with fibromyalgia; thus, any abnormalities may suggest the presence of one of the systemic illnesses discussed below.",
"   </p>",
"   <p>",
"    A wide variety of disorders may be associated with diffuse or localized myalgia. An overview of the approach to the evaluation of patients presenting with myalgia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/23/2424?source=see_link\">",
"     \"Approach to the patient with myalgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYSTEMIC AND RHEUMATIC DISEASES MISTAKEN FOR FIBROMYALGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia may be incorrectly diagnosed as any one of a variety of systemic and rheumatic diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis, Sj&ouml;gren's syndrome, and systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatic diseases such as rheumatoid arthritis (RA), Sj&ouml;gren&rsquo;s syndrome (SS), and systemic lupus erythematosus (SLE) may present with generalized arthralgias, myalgias, and fatigue and, like fibromyalgia, most often affect younger women (",
"    <a class=\"graphic graphic_table graphicRef50712 \" href=\"mobipreview.htm?14/44/15051\">",
"     table 1",
"    </a>",
"    ). However, characteristic features of RA, such as multiple joint swelling, or of SLE, such as facial rash and multisystemic inflammation, do not occur in fibromyalgia.",
"   </p>",
"   <p>",
"    A careful history and physical examination, rather than &ldquo;screening&rdquo; serologic blood tests, should be sufficient to differentiate fibromyalgia from a connective tissue disease. Thus, unless there is strong clinical suspicion of a systemic rheumatic disorder, routine ordering of serologic tests is NOT recommended; these tests, such as antinuclear antibody (ANA) and rheumatoid factor (RF), may be positive in healthy individuals and in many other diseases. For example, approximately 10 to 15 percent of patients with fibromyalgia have a positive antinuclear antibody (ANA) test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/5\">",
"     5",
"    </a>",
"    ]. However, 5 to 10 percent of healthy women also have a positive ANA, at least at low titer. Therefore, the predictive value of a positive antinuclear antibody is poor in patients who have no signs or symptoms of SLE. If there is clinical confusion regarding the differential diagnosis of fibromyalgia with SLE or with other systemic connective tissue diseases, more specific serologic tests, such as an anti-DNA antibody test, should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=see_link\">",
"     \"Origin and utility of measurement of rheumatoid factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibromyalgia occurs more commonly in these systemic immune diseases than in the general population and can affect disease assessment. This is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort of 173 patients with SLE, approximately 30 percent of the patients met criteria for fibromyalgia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/6\">",
"       6",
"      </a>",
"      ]. There was a strong association between the number of tender points and health status.",
"     </li>",
"     <li>",
"      In a large rheumatic disease database, fibromyalgia was present in 22 percent of patients with SLE and in 17 percent of those with RA and other forms of arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of patients with RA and FM, the presence of FM made evaluation of RA more difficult, resulting in an overestimate of disease activity using the DAS28 composite score [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The future development of fibromyalgia was evaluated in 9739 patients with RA during 42,591 patient-years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/9\">",
"       9",
"      </a>",
"      ]. Seven percent of RA patients satisfied criteria for fibromyalgia at last observation, and 20 percent satisfied criteria at some point during follow-up. The incidence rate was 5.3 per 100 patients-years (95% CI 5.1-5.6); rates were similar in men and women. Multiple factors predicted the future development of fibromyalgia, including psychosocial issues, depression, comorbidity, more severe RA, and greater baseline fibromyalgia symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ankylosing spondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankylosing spondylitis or other inflammatory back conditions may present with axial skeletal pain and stiffness similar to that of fibromyalgia and may be misdiagnosed as fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/10\">",
"     10",
"    </a>",
"    ]. However, spinal motion in fibromyalgia is generally normal, and there are characteristic imaging and radiologic features of ankylosing spondylitis and the other seronegative spondyloarthropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13640?source=see_link\">",
"     \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Polymyalgia rheumatica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymyalgia rheumatica (PMR) may mimic fibromyalgia, although this disorder can be differentiated by the history and laboratory studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following features help differentiate PMR and FM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with PMR tend to be older at onset and to present more with generalized stiffness than with severe, widespread pain.",
"     </li>",
"     <li>",
"      An elevated ESR is present in the vast majority of patients with PMR but is normal in patients with fibromyalgia.",
"     </li>",
"     <li>",
"      Patients with PMR, but not those with fibromyalgia, respond extremely well to modest doses of glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/11\">",
"       11",
"      </a>",
"      ]. However, glucocorticoid withdrawal in PMR or any rheumatic condition may cause symptoms that are similar to those of fibromyalgia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inflammatory myositis and metabolic myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia is distinguished from inflammatory myositis and the metabolic myopathies by the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myositis and the myopathies cause muscle weakness and muscle fatigue but are not usually associated with diffuse pain.",
"     </li>",
"     <li>",
"      Patients with fibromyalgia do not have significant muscle weakness, other than that related to pain or disuse.",
"     </li>",
"     <li>",
"      In contrast to myositis, patients with fibromyalgia have normal muscle enzyme tests and normal or nonspecific histopathologic findings on muscle biopsy. Muscle biopsies should not be performed unless there is clinical evidence suggestive of an inflammatory or metabolic myopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia may mimic a chronic viral infection such as infectious mononucleosis. Fibromyalgia, as well as chronic fatigue syndrome (CFS), has been noted to follow or accompany well-documented infections, including human immunodeficiency virus (HIV) infection, human T-lymphotropic virus (HTLV) infection, hepatitis, and Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Approximately 25 to 40 percent of patients with documented Lyme disease who are treated appropriately with antibiotics will develop persistent pain and fatigue, consistent with fibromyalgia and CFS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]. However, there has been no evidence of persistent microbial infection in the vast majority of these patients. Furthermore, antibiotics are not effective in this &ldquo;post-Lyme&rdquo;",
"    <span class=\"nowrap\">",
"     fibromyalgia/CFS",
"    </span>",
"    condition. Thus, patients should not be repeatedly treated with prolonged courses of antibiotics if they have no clinical or serologic evidence of active Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=see_link&amp;anchor=H20#H20\">",
"     \"Musculoskeletal manifestations of Lyme disease\", section on 'Post-lyme disease syndrome (chronic lyme disease) and fibromyalgia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism may be difficult to distinguish from fibromyalgia, since patients with hypothyroidism often complain of generalized aches, fatigue, and interrupted sleep. Thus, thyroid function studies (usually a serum thyroid stimulating hormone [TSH] level) should be routinely obtained during the initial evaluation of a patient with suspected fibromyalgia; the vast majority of fibromyalgia patients have normal thyroid tests. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibromyalgia may also be a presenting manifestation of hypothyroidism, and thyroid autoantibodies are common in patients with fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/16\">",
"     16",
"    </a>",
"    ]. However, correcting the thyroid abnormality does not usually ameliorate the fibromyalgia symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other endocrine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other endocrine disorders that may present with symptoms similar to fibromyalgia include hyperparathyroidism and Cushing&rsquo;s syndrome. Hyperparathyroidism is recognized by the presence of hypercalcemia, while Cushing&rsquo;s syndrome presents with characteristic facial and skin features and is associated with muscle weakness rather than pain. Adrenal insufficiency causes severe exhaustion but is not typically associated with chronic, widespread pain. Some studies, but not others, have suggested that patients with vitamin D deficiency without evidence of osteomalacia may also experience symptoms of chronic musculoskeletal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. A 2011 systematic review found no conclusive evidence for an association of vitamin D deficiency and fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29667332\">",
"    <span class=\"h2\">",
"     Statin-associated myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 10 to 30 percent of subjects treated with statins will experience nonspecific muscle discomfort. Those with preexisting fibromyalgia are more likely to develop statin-associated muscle pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Peripheral neuropathies, entrapment syndromes, and neurologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathies, entrapment syndromes (such as carpal tunnel syndrome), and neurologic disorders (such as multiple sclerosis and myasthenia gravis) may mimic fibromyalgia (",
"    <a class=\"graphic graphic_table graphicRef50712 \" href=\"mobipreview.htm?14/44/15051\">",
"     table 1",
"    </a>",
"    ). Multiple sclerosis and myasthenia gravis are associated with post-exercise muscle fatigue, as well as generalized fatigue. However, chronic, widespread pain is unusual.",
"   </p>",
"   <p>",
"    Patients with fibromyalgia are frequently mistakenly diagnosed with one of these neurologic diseases, since they may complain of numbness and tingling, often involving the neck and radiating down the arm, suggesting cervical radiculopathy. These symptoms of paresthesias, as well as subjective cognitive dysfunction, often lead to costly and invasive neurologic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/23\">",
"     23",
"    </a>",
"    ]. A careful neurologic examination should differentiate fibromyalgia from neurologic disease. A report did find frequent objective neurologic abnormalities in patients with fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/24\">",
"     24",
"    </a>",
"    ]. Poor balance or coordination; tingling or weakness in the arms or legs; and numbness in any part of the body correlated with appropriate neurologic examination findings in the FM group. However, unless there is evidence of associated nerve compression or of cervical or lumbar spinal stenosis, extensive testing including plain radiographs, electromyography (EMG), nerve conduction velocities, computerized tomography (CT) scans, nuclear scans, or magnetic resonance imaging (MRI) is not generally necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS OF OVERLAPPING SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most confusing conditions in the differential diagnosis of fibromyalgia include a variety of illnesses that overlap with fibromyalgia and that may be even considered to be part of the fibromyalgia spectrum. These include myofascial pain syndrome; functional somatic syndromes, including irritable bowel syndrome, migraine, and chronic fatigue syndrome (CFS); and mood and sleep disorders (",
"    <a class=\"graphic graphic_table graphicRef56019 \" href=\"mobipreview.htm?15/57/16283\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78935 \" href=\"mobipreview.htm?11/9/11420\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/25-36\">",
"     25-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Myofascial pain syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myofascial pain syndrome, sometimes termed repetitive strain syndrome, overlaps considerably with fibromyalgia (",
"    <a class=\"graphic graphic_table graphicRef81771 \" href=\"mobipreview.htm?10/37/10843\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/26,28,37-39\">",
"     26,28,37-39",
"    </a>",
"    ]. Patients with myofascial pain syndrome complain of pain in one anatomic region, such as the right side of the neck and shoulder, with tenderness being confined to that area. Many of the original reports of fibromyalgia actually described what would have subsequently been termed myofascial pain syndrome. Some of the confusion lies in the differentiation between trigger points and tender points.",
"   </p>",
"   <p>",
"    Myofascial pain is defined by the presence of trigger points that are found in a taut band in the muscle (",
"    <a class=\"graphic graphic_figure graphicRef81019 \" href=\"mobipreview.htm?22/32/23040\">",
"     figure 1",
"    </a>",
"    ). A characteristic referral pain pattern is activated when pressure is applied to a trigger point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/26,28,38\">",
"     26,28,38",
"    </a>",
"    ]. Some experts also insist upon the presence of a local twitch response, a visible or palpable contraction of the muscle produced by a rapid snap of the examining finger to the taut band of muscle. By contrast, tender points, as seen in fibromyalgia, are soft tissue sites that are excessively tender on manual palpation. However, the reliability of the trigger point examination has been questioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/28,37,39\">",
"     28,37,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study, for example, employed experts in myofascial pain syndrome and fibromyalgia to perform tender point examinations on three groups of patients: seven with fibromyalgia, eight with myofascial pain syndrome, and eight healthy people. They found local tenderness to be common in both disease groups (65 to 82 percent), although more common in patients with myofascial pain. Active trigger points were found in 38 and 23 percent of patients with fibromyalgia and myofascial pain syndrome, respectively (using a liberal definition of trigger point). Taut muscle bands and muscle twitches were common (50 and 30 percent respectively) and were found in the healthy controls as well [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study of similar design found that dolorimetry and palpation were sufficiently reliable to discriminate control patients from patients with myofascial pain and fibromyalgia but may not discriminate between the two diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most importantly, there is no accepted reference standard for the diagnosis of trigger points, and data on the reliability of physical examination for trigger points are conflicting. A systematic review concluded that the physical examination cannot be recommended as a reliable test for the diagnosis of trigger points [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myofascial pain syndromes may include other common regional pain disorders such as tension headaches, idiopathic low back and cervical strain disorders, repetitive strain syndromes, occupational overuse syndrome, cumulative trauma disorder, work-related musculoskeletal disorder, and temporomandibular joint (TMJ) syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/27,29,30\">",
"     27,29,30",
"    </a>",
"    ]. In the head and neck, the pain may be associated with unexplained dizziness and with neurocognitive disturbances. The etiology of these complaints is not understood, although some neurovestibular abnormalities are often found in patients with TMJ and myofascial pain of the head. These poorly understood pain disorders are also associated with fatigue, sleep abnormalities, and mood disturbances, suggesting that myofascial pain may be just a localized or regional form of fibromyalgia.",
"   </p>",
"   <p>",
"    Chronic, unexplained pelvic and urethral pain, sometimes termed the female urethral syndrome, is often considered to be a variation of myofascial pain. Considered together with the disorders discussed above, myofascial pain syndrome may be one of the most common causes of chronic pain.",
"   </p>",
"   <p>",
"    Myofascial pain is generally treated similarly to fibromyalgia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    .) Myofascial pain may respond well to local treatment methods such as application of a cold spray and passive stretch of the involved muscle. Trigger point injections, using dry needling, saline, or botulinum toxin, have been effective in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/26,27,30\">",
"     26,27,30",
"    </a>",
"    ]. This type of treatment is not felt to be as successful in fibromyalgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Functional somatic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia is often present in patients together with other common functional somatic syndromes, including chronic fatigue syndrome (CFS), irritable bowel syndrome (IBS), migraine, and temporomandibular joint (TMJ) disorder, as well as chronic bladder and pelvic pain syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/25,31-33,40,41\">",
"     25,31-33,40,41",
"    </a>",
"    ]. The prevalence of fibromyalgia in each of these disorders varies from 20 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Demographic, clinical, and potential pathophysiologic characteristics of CFS, IBS, and other functional somatic syndromes are very similar to those of fibromyalgia. Each of these conditions is diagnosed when other diseases have been excluded, and they tend to be controversial because of the absence of a specific diagnostic test or of objective pathophysiologic abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31031?source=see_link\">",
"     \"Pathogenesis of fibromyalgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simple questions to screen for each of the common functional somatic syndromes have been suggested that can be useful in determining whether additional evaluation is warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic fatigue syndrome &mdash; Have you had unexplained, persistent, or relapsing fatigue for at least six months? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30825?source=see_link\">",
"       \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Irritable bowel syndrome &mdash; Have you had abdominal discomfort or pain accompanied or affected by constipation or diarrhea for three or more months in the past year? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22455?source=see_link\">",
"       \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Temporomandibular disorders &mdash; Have you had recurrent",
"      <span class=\"nowrap\">",
"       facial/jaw",
"      </span>",
"      pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      limitation in jaw opening occurring in the past six months? (See",
"      <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=see_link\">",
"       \"Temporomandibular disorders in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tension and migraine headache &mdash; Have you had recurrent headaches (at least five for migraine, at least 10 for tension-type) lasting 30 minutes occurring in the past six months? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37830?source=see_link\">",
"       \"Overview of chronic daily headache\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      Interstitial cystitis &mdash; Have you had symptoms for over nine months of bladder pain, urinary urgency and frequency (voiding more than eight times during the day or more than two times during the night), and a negative urine culture? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8330?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these illnesses causes pain, although the primary area of pain varies (for example, chronic widespread pain in fibromyalgia, abdominal pain in irritable bowel syndrome, and jaw pain in temporomandibular disorder). Fatigue, cognitive disturbances, and generalized allodynia and hyperalgesia are characteristic of fibromyalgia, irritable bowel syndrome, and chronic fatigue syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/2,4,44-46\">",
"     2,4,44-46",
"    </a>",
"    ]. Furthermore, imaging studies in these functional pain disorders reveal similar changes related to augmented pain perception in the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mood disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since many symptoms of fibromyalgia, including depression, fatigue, lack of energy, and sleep disturbances, are characteristic of mood disturbances, many clinicians believe that fibromyalgia is primarily a psychiatric illness. However, observations suggest that fibromyalgia is not a psychiatric illness but that mood disturbances are important in the expression and outcome of this condition.",
"   </p>",
"   <p>",
"    Mood disorders are more prominent in fibromyalgia than in rheumatic diseases, such as RA. Approximately 25 percent of patients with fibromyalgia have concurrent major depression, and 50 percent have a lifetime history of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/1,2,45,46,48\">",
"     1,2,45,46,48",
"    </a>",
"    ]. The greater incidence of mood disorders is especially striking in tertiary referral patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/46\">",
"     46",
"    </a>",
"    ]. An informal evaluation of mood should be part of the initial evaluation of any patient with fibromyalgia, with a more formal assessment by a mental health professional in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sleep disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with FM have nonrestorative sleep. Sleep disturbances are also very common in patients with fibromyalgia, although the most common is a nonspecific interruption in stage 4 sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/49\">",
"     49",
"    </a>",
"    ]. However, primary sleep disturbances, including sleep apnea, restless leg syndrome, and repetitive leg movement disorders are quite common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35608/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, a careful sleep history should be obtained in patients with fibromyalgia symptoms. Patients with possible sleep apnea or nocturnal myoclonus should be referred to a sleep clinic for further evaluation and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"       \"Patient information: Fibromyalgia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1751917\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial approach to the differential diagnosis in a patient with complaints suggestive of fibromyalgia is a thorough history and physical examination. In fibromyalgia, the physical examination is unrevealing other than tenderness in muscles and soft tissue. Baseline blood tests should be limited to a complete blood count, erythrocyte sedimentation rate, standard blood chemistries, and thyroid function tests. These tests are all usually normal in patients with fibromyalgia; thus, any abnormalities may suggest the presence of a systemic illnesses other than fibromyalgia. (See",
"      <a class=\"local\" href=\"#H1752243\">",
"       'Approach to the differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history and physical examination, rather than serologic testing, should be sufficient to differentiate fibromyalgia from most rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus, and Sj&ouml;gren&rsquo;s syndrome. Selected laboratory or imaging findings, in addition to the history and physical examination, may be useful in distinguishing fibromyalgia from ankylosing spondylitis, polymyalgia rheumatica, inflammatory or metabolic myopathies, hypothyroidism, and other endocrine disorders. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Systemic and rheumatic diseases mistaken for fibromyalgia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Rheumatoid arthritis, Sj&ouml;gren's syndrome, and systemic lupus erythematosus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Ankylosing spondylitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Polymyalgia rheumatica'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Inflammatory myositis and metabolic myopathies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Hypothyroidism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Other endocrine disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral neuropathies, entrapment syndromes (such as carpal tunnel syndrome), and neurologic disorders (such as multiple sclerosis and myasthenia gravis) may mimic fibromyalgia (",
"      <a class=\"graphic graphic_table graphicRef50712 \" href=\"mobipreview.htm?14/44/15051\">",
"       table 1",
"      </a>",
"      ). Multiple sclerosis and myasthenia gravis are associated with post-exercise muscle fatigue, as well as generalized fatigue. However, chronic, widespread pain is unusual. A careful neurologic examination should differentiate fibromyalgia from neurologic disease. Unless there is evidence of associated nerve compression or of cervical or lumbar spinal stenosis, extensive testing including plain radiographs, electromyography (EMG), nerve conduction velocities, CT scans, nuclear scans, or MRI is not generally necessary. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Peripheral neuropathies, entrapment syndromes, and neurologic disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most confusing conditions in the differential diagnosis of fibromyalgia include a variety of illnesses that overlap with fibromyalgia and that may be even considered to be part of the fibromyalgia spectrum. These include myofascial pain syndrome; functional somatic syndromes, including irritable bowel syndrome, migraine, and chronic fatigue syndrome; and mood and sleep disorders (",
"      <a class=\"graphic graphic_table graphicRef56019 \" href=\"mobipreview.htm?15/57/16283\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78935 \" href=\"mobipreview.htm?11/9/11420\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis of overlapping syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myofascial pain syndrome, sometimes termed repetitive strain syndrome, overlaps considerably with fibromyalgia (",
"      <a class=\"graphic graphic_table graphicRef81771 \" href=\"mobipreview.htm?10/37/10843\">",
"       table 4",
"      </a>",
"      ). Patients with myofascial pain syndrome complain of pain in one anatomic region, with tenderness being confined to that area. Some of the confusion lies in the differentiation between trigger points and tender points. Myofascial pain is defined by the presence of trigger points that are found in a taut band in the muscle (",
"      <a class=\"graphic graphic_figure graphicRef81019 \" href=\"mobipreview.htm?22/32/23040\">",
"       figure 1",
"      </a>",
"      ). A characteristic referral pain pattern is activated when pressure is applied to a trigger point. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Myofascial pain syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibromyalgia is often present in patients together with other common functional somatic syndromes, including chronic fatigue syndrome (CFS), irritable bowel syndrome (IBS), migraine, and temporomandibular joint disorder, as well as chronic bladder and pelvic pain syndromes. Demographic, clinical, and potential pathophysiologic characteristics of CFS, IBS, and other functional somatic syndromes are very similar to those of fibromyalgia. Simple questions to screen for each of the common functional somatic syndromes have been suggested that can be useful in determining whether additional evaluation is warranted. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Functional somatic syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mood disorders are common in fibromyalgia. Approximately 25 percent of patients with fibromyalgia have concurrent major depression, and 50 percent have a lifetime history of depression. An informal evaluation of mood should be part of the initial evaluation of any patient with fibromyalgia, with a more formal assessment by a mental health professional in selected patients. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Mood disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleep disturbances are common in patients with fibromyalgia, including a nonspecific interruption in stage 4 sleep and primary sleep disturbances, such as sleep apnea, restless leg syndrome, and repetitive leg movement disorders. A careful sleep history should be obtained in patients with fibromyalgia symptoms. Patients with possible sleep apnea or nocturnal myoclonus should be referred to a sleep clinic for further evaluation and treatment. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Sleep disturbance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/1\">",
"      Goldenberg DL. Fibromyalgia syndrome. An emerging but controversial condition. JAMA 1987; 257:2782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/2\">",
"      Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol 2007; 34:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/3\">",
"      Hwang E, Barkhuizen A. Update on rheumatologic mimics of fibromyalgia. Curr Pain Headache Rep 2006; 10:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/4\">",
"      Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol 2003; 17:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/5\">",
"      Dinerman H, Goldenberg DL, Felson DT. A prospective evaluation of 118 patients with the fibromyalgia syndrome: prevalence of Raynaud's phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction. J Rheumatol 1986; 13:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/6\">",
"      Akkasilpa S, Goldman D, Magder LS, Petri M. Number of fibromyalgia tender points is associated with health status in patients with systemic lupus erythematosus. J Rheumatol 2005; 32:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/7\">",
"      Wolfe F, Petri M, Alarc&oacute;n GS, et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol 2009; 36:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/8\">",
"      Coury F, Rossat A, Tebib A, et al. Rheumatoid arthritis and fibromyalgia: a frequent unrelated association complicating disease management. J Rheumatol 2009; 36:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/9\">",
"      Wolfe F, H&auml;user W, Hassett AL, et al. The development of fibromyalgia--I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 2011; 152:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/10\">",
"      Fitzcharles MA, Boulos P. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology (Oxford) 2003; 42:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/11\">",
"      Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985; 12:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/12\">",
"      Goldenberg DL. Do infections trigger fibromyalgia? Arthritis Rheum 1993; 36:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/13\">",
"      Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993; 269:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/14\">",
"      Cruz BA, Catalan-Soares B, Proietti F. Higher prevalence of fibromyalgia in patients infected with human T cell lymphotropic virus type I. J Rheumatol 2006; 33:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/15\">",
"      Feder HM Jr, Johnson BJ, O'Connell S, et al. A critical appraisal of \"chronic Lyme disease\". N Engl J Med 2007; 357:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/16\">",
"      Ribeiro LS, Proietti FA. Interrelations between fibromyalgia, thyroid autoantibodies, and depression. J Rheumatol 2004; 31:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/17\">",
"      Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/18\">",
"      Lyman D. Undiagnosed vitamin D deficiency in the hospitalized patient. Am Fam Physician 2005; 71:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/19\">",
"      Block SR. Vitamin D deficiency is not associated with nonspecific musculoskeletal pain syndromes including fibromyalgia. Mayo Clin Proc 2004; 79:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/20\">",
"      Daniel D, Pirotta MV. Fibromyalgia--should we be testing and treating for vitamin D deficiency? Aust Fam Physician 2011; 40:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/21\">",
"      Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011; 78:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/22\">",
"      Tomaszewski M, Stpie KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep 2011; 63:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/23\">",
"      Simms RW, Goldenberg DL. Symptoms mimicking neurologic disorders in fibromyalgia syndrome. J Rheumatol 1988; 15:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/24\">",
"      Watson NF, Buchwald D, Goldberg J, et al. Neurologic signs and symptoms in fibromyalgia. Arthritis Rheum 2009; 60:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/25\">",
"      Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000; 160:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/26\">",
"      Hong CZ. Treatment of myofascial pain syndrome. Curr Pain Headache Rep 2006; 10:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/27\">",
"      Borg-Stein J. Treatment of fibromyalgia, myofascial pain, and related disorders. Phys Med Rehabil Clin N Am 2006; 17:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/28\">",
"      Tunks E, McCain GA, Hart LE, et al. The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. J Rheumatol 1995; 22:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/29\">",
"      Wigley R. Can fibromyalgia be separated from regional pain syndrome affecting the arm? J Rheumatol 1999; 26:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/30\">",
"      Fern&aacute;ndez-de-Las-Pe&ntilde;as C, Alonso-Blanco C, Cuadrado ML, et al. Myofascial trigger points and their relationship to headache clinical parameters in chronic tension-type headache. Headache 2006; 46:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/31\">",
"      Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/32\">",
"      Goldenberg DL, Simms RW, Geiger A, Komaroff AL. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum 1990; 33:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/33\">",
"      Cole JA, Rothman KJ, Cabral HJ, et al. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol 2006; 6:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/34\">",
"      Caldarella MP, Giamberardino MA, Sacco F, et al. Sensitivity disturbances in patients with irritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2006; 101:2782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/35\">",
"      Kurland JE, Coyle WJ, Winkler A, Zable E. Prevalence of irritable bowel syndrome and depression in fibromyalgia. Dig Dis Sci 2006; 51:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/36\">",
"      Amital D, Fostick L, Polliack ML, et al. Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities? J Psychosom Res 2006; 61:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/37\">",
"      Wolfe F, Simons DG, Fricton J, et al. The fibromyalgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. J Rheumatol 1992; 19:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/38\">",
"      Basford JR, An KN. New techniques for the quantification of fibromyalgia and myofascial pain. Curr Pain Headache Rep 2009; 13:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/39\">",
"      Lucas N, Macaskill P, Irwig L, et al. Reliability of physical examination for diagnosis of myofascial trigger points: a systematic review of the literature. Clin J Pain 2009; 25:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/40\">",
"      Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001; 134:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/41\">",
"      Almansa C, Rey E, S&aacute;nchez RG, et al. Prevalence of functional gastrointestinal disorders in patients with fibromyalgia and the role of psychologic distress. Clin Gastroenterol Hepatol 2009; 7:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/42\">",
"      Fraga BP, Santos EB, Farias Neto JP, et al. Signs and symptoms of temporomandibular dysfunction in fibromyalgic patients. J Craniofac Surg 2012; 23:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/43\">",
"      Rodr&iacute;guez MA, Afari N, Buchwald DS, National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Urological Chronic Pelvic Pain. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol 2009; 182:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/44\">",
"      Tietjen GE, Brandes JL, Peterlin BL, et al. Allodynia in migraine: association with comorbid pain conditions. Headache 2009; 49:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/45\">",
"      Giesecke T, Gracely RH, Williams DA, et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005; 52:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/46\">",
"      Aaron LA, Bradley LA, Alarc&oacute;n GS, et al. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum 1996; 39:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/47\">",
"      Chalaye P, Goffaux P, Bourgault P, et al. Comparing pain modulation and autonomic responses in fibromyalgia and irritable bowel syndrome patients. Clin J Pain 2012; 28:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/48\">",
"      Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50:2974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/49\">",
"      Moldofsky H. The significance of dysfunctions of the sleeping/waking brain to the pathogenesis and treatment of fibromyalgia syndrome. Rheum Dis Clin North Am 2009; 35:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35608/abstract/50\">",
"      Chervin RD, Teodorescu M, Kushwaha R, et al. Objective measures of disordered sleep in fibromyalgia. J Rheumatol 2009; 36:2009.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5625 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35608=[""].join("\n");
var outline_f34_49_35608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1751917\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752243\">",
"      APPROACH TO THE DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYSTEMIC AND RHEUMATIC DISEASES MISTAKEN FOR FIBROMYALGIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rheumatoid arthritis, Sj&ouml;gren's syndrome, and systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ankylosing spondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inflammatory myositis and metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29667332\">",
"      Statin-associated myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Peripheral neuropathies, entrapment syndromes, and neurologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS OF OVERLAPPING SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Myofascial pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Functional somatic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mood disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sleep disturbance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1751917\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5625\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5625|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/32/23040\" title=\"figure 1\">",
"      Trigger points myofascial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5625|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/44/15051\" title=\"table 1\">",
"      Differential dx fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/57/16283\" title=\"table 2\">",
"      Sx fibromyalgia chronic fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/9/11420\" title=\"table 3\">",
"      Sxs distinguish CFS FM and TMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/37/10843\" title=\"table 4\">",
"      Fibromyalgia v myofascial pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/23/2424?source=related_link\">",
"      Approach to the patient with myalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30825?source=related_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7896?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13640?source=related_link\">",
"      Diagnosis and differential diagnosis of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14586?source=related_link\">",
"      Initial treatment of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=related_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=related_link\">",
"      Origin and utility of measurement of rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37830?source=related_link\">",
"      Overview of chronic daily headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31031?source=related_link\">",
"      Pathogenesis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8330?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=related_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=related_link\">",
"      Temporomandibular disorders in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19350?source=related_link\">",
"      Treatment and prognosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5786?source=related_link\">",
"      Treatment of fibromyalgia in adults not responsive to initial therapies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_49_35609="Causes of hematuria";
var content_f34_49_35609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Causes of hematuria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 704px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Hematuria may not be attributed solely to alterations in coagulation or platelet function until competing causes have been ruled out.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Kurtz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35609=[""].join("\n");
var outline_f34_49_35609=null;
var title_f34_49_35610="Antiplatelet agents in acute ST elevation myocardial infarction";
var content_f34_49_35610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiplatelet agents in acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/49/35610/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/49/35610/contributors\">",
"     A Michael Lincoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/49/35610/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/49/35610/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/49/35610/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/49/35610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/49/35610/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/49/35610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of an atherosclerotic plaque is the usual initiating event in an acute coronary syndrome (ACS). Persistent thrombotic occlusion at the site of plaque rupture results in acute myocardial infarction (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    ). The role of platelets in thrombus formation during ACS is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Normal platelet function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4167?source=see_link\">",
"     \"The role of platelets in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the evidence that antiplatelet therapy is beneficial in patients with an acute ST-elevation myocardial infarction (STEMI), and will provide recommendations for its use. Information regarding antiplatelet agents in non-ST elevation ACS (unstable angina or non-ST elevation MI) and the role of anticoagulant therapy in STEMI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ANTIPLATELET AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet agents can interfere with a number of platelet functions, including aggregation, release of granule contents, and platelet-mediated vascular constriction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3594?source=see_link\">",
"     \"Effect of cardiac drugs on platelet function\"",
"    </a>",
"    .) They can be classified according to their mechanism of action (",
"    <a class=\"graphic graphic_figure graphicRef75709 \" href=\"mobipreview.htm?28/48/29440\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      and related compounds (nonsteroidal antiinflammatory drugs and sulfinpyrazone) block the enzyme cyclooxygenase (prostaglandin",
"      <span class=\"nowrap\">",
"       G/H",
"      </span>",
"      synthase) that mediates the first step in the biosynthesis of prostaglandins and thromboxanes (including TXA2) from arachidonic acid (",
"      <a class=\"graphic graphic_figure graphicRef66146 \" href=\"mobipreview.htm?33/29/34269\">",
"       figure 2",
"      </a>",
"      ). Thromboxane A2 is a potent stimulator of platelet aggregation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of hemostasis\", section on 'Platelet aggregation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The platelet P2Y12 receptor blockers",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      , and cangrelor block the binding of ADP to a specific platelet receptor P2Y12, thereby inhibiting activation of the GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      complex and platelet aggregation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      (GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa)",
"      </span>",
"      antibodies and receptor antagonists inhibit the final common pathway of platelet aggregation (the cross-bridging of platelets by fibrinogen binding to the GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    has established benefit in a variety of cardiovascular disorders including primary and secondary prevention of coronary heart disease, transient ischemic attack, and stroke and in the acute therapy of patients with an ACS. It should be started immediately upon presentation with acute STEMI and continued indefinitely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antiplatelet activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    appears to be mediated principally through inhibition of the synthesis of thromboxane A2. Platelets do not synthesize new enzymes and as a result, the functional defect induced by aspirin persists for the life of the platelet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H2#H2\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evidence of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy begun during the first 24 hours after acute STEMI was initially demonstrated in the Second International Study of Infarct Survival (ISIS-2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/2\">",
"     2",
"    </a>",
"    ]. ISIS-2 randomly assigned 17,187 patients in a 2-by-2 factorial design to oral aspirin (160",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 30 days), intravenous streptokinase, both agents, or neither drug. Aspirin therapy resulted in a highly-significant reduction in five-week vascular mortality (23 percent reduction), which was equivalent to that seen with streptokinase (25 percent reduction) and additive when streptokinase and aspirin were administered together (42 percent reduction). The absolute mortality reduction was 2.4 vascular deaths prevented per 100 patients treated. Aspirin therapy in ISIS-2 was also associated with significant reductions in the incidence of nonfatal reinfarction (1.0 versus 2.0 percent) and stroke (0.3 versus 0.6 percent). There was no increase in the risk of major bleeding or hemorrhagic stroke in patients receiving aspirin.",
"   </p>",
"   <p>",
"    The Antithrombotic Trialists' Collaboration reviewed the effect of antiplatelet therapy, mostly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (in doses ranging from 75 to 1500 mg daily) in nearly 200,000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/3\">",
"     3",
"    </a>",
"    ]. Antiplatelet therapy produced a significant 30 percent reduction (10.4 versus 14.2 percent) in the combined endpoint of subsequent nonfatal myocardial infarction (MI), nonfatal stroke, or vascular death in over 19,000 patients with acute myocardial infarction (",
"    <a class=\"graphic graphic_table graphicRef56243 \" href=\"mobipreview.htm?42/34/43564\">",
"     table 1",
"    </a>",
"    ). This study did not find a significant difference in efficacy between lower and higher daily doses (75-325 versus 500 to 1500 mg). Another important contribution of this study was the finding that the addition of a second antiplatelet agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , or intravenous glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) significantly lowered the combined endpoint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial loading dose of 162 to 325 mg of uncoated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should be given as soon as possible to any patient thought to have an ACS. At this dose, aspirin produces a rapid antithrombotic effect due to immediate and almost complete inhibition of thromboxane A2 production. The first tablet should be chewed or crushed to establish a high blood level quickly. More rapid absorption occurs with nonenteric coated formulations. There is no evidence that higher doses are more effective but they may lead to greater gastric irritation. Aspirin (75 to 162 mg once a day) should be continued indefinitely for secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H20#H20\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Dosing and cardiovascular benefit'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H6#H6\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Dosing and bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our experts recommend this lower dose (75 to 162",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , based principally on CURRENT OASIS 7 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/5\">",
"     5",
"    </a>",
"    ], in which there was no significant difference in cardiovascular outcomes, but lower risk of gastrointestinal bleeding, with low dose (75 to 100 mg daily) aspirin (compared with higher dose of 300 to 325 mg daily). This finding was irrespective of whether ACS patients received percutaneous coronary intervention or not.(See",
"    <a class=\"local\" href=\"#H514072657\">",
"     'Dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    , we recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    at a dose &le;100 mg daily, based on results in the PLATO study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/6\">",
"     6",
"    </a>",
"    ] and as listed in the United States Food and Drug Administration package insert for the drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H26#H26\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Ticagrelor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    therapy may be associated with gastrointestinal intolerance, including bleeding, allergy (primarily manifested as bronchospasm or asthma), or worsening of preexistent bleeding outside the gastrointestinal tract. Gastrointestinal side effects such as dyspepsia and nausea are infrequent with the low doses used in this setting. Patients who develop gastrointestinal side effects should be treated with a proton pump inhibitor and are usually then able to tolerate a lower dose (75 to 100 mg of aspirin per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/7\">",
"     7",
"    </a>",
"    ]. Enteric-coated aspirin may be of some benefit, but it does not protect against gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H21#H21\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Aspirin formulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     P2Y12 RECEPTOR BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thienopyridines",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , and the cyclopentyltriazolopyrimidine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    , block the adenosine diphosphate receptor P2Y12 on platelets (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link\">",
"     \"Platelet biology\"",
"    </a>",
"    ). Most evidence shows that the antiplatelet benefits of these agents are additive to those of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , irrespective of whether the patient receives fibrinolytic therapy, primary percutaneous coronary intervention (PCI), or no reperfusion. In most cases of STEMI, this category of drug should be started immediately on presentation and continued for up to one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     With fibrinolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit from fibrinolytic therapy in patients with STEMI is limited by the failure to achieve normal (TIMI grade III) flow in 40 to 50 percent of infarct-related arteries. This is important because only the restoration of normal flow is associated with improved outcomes. In addition, threatened reocclusion occurs in 5 to 15 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\", section on 'Threatened reocclusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=see_link&amp;anchor=H2#H2\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'Markers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link&amp;anchor=H69243493#H69243493\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Concomitant therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations provided support for the hypothesis that more aggressive (than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone) antiplatelet therapy might improve outcomes following fibrinolytic therapy. Two randomized trials of patients treated with fibrinolytic therapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <span class=\"nowrap\">",
"     (COMMIT/CCS-2",
"    </span>",
"    and CLARITY-TIMI 28) showed clear evidence of benefit from early administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in patients also treated with aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the",
"      <span class=\"nowrap\">",
"       COMMIT/CCS-2",
"      </span>",
"      trial, 45,582 patients with a suspected acute MI (93 percent with ST elevation or left bundle branch block) were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/9\">",
"       9",
"      </a>",
"      ]. One-half of patients received fibrinolytic therapy and all patients were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . At 16 days the primary endpoints of death and the composite of death, repeat MI, or stroke were significantly lower in the patients who received clopidogrel (7.5 versus 8.1 and 9.3 versus 10.1 percent, respectively).",
"     </li>",
"     <li>",
"      In the CLARITY-TIMI 28 trial, 3491 patients with STEMI age 75 years or younger who received fibrinolytic therapy,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/8\">",
"       8",
"      </a>",
"      ]. The primary endpoint was a composite of an occluded infarct-related artery (TIMI grade",
"      <span class=\"nowrap\">",
"       0/I)",
"      </span>",
"      or death or recurrent MI before angiography, two to eight days after therapy was begun. Clopidogrel significantly reduced the primary endpoint (15.0 versus 21.7 percent with placebo; 36 percent odds reduction, 95% CI 27 to 47 percent). The rate of cardiovascular death, MI, or recurrent ischemia leading to urgent revascularization was also significantly reduced by 20 percent. There were no differences between the groups in the rates of major bleeding or intracranial hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     Ticagrelor",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    have not been evaluated in STEMI patients treated with fibrinolysis. Our authors and reviewers do not recommend their use with fibrinolytic therapy due to the potential for increased bleeding compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . In particular, we are concerned about the potential for intracranial hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     With primary PCI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547672752\">",
"    <span class=\"h3\">",
"     Clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials designed to evaluate the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    compared to aspirin alone in STEMI patients treated with primary PCI. Indirect evidence of benefit comes from the prespecified subset analysis (PCI-CLARITY) of patients enrolled in CLARITY-TIMI 28 (discussed above) who underwent PCI and from randomized trials in patients with a non-ST elevation ACS. PCI-CLARITY, a subset of CLARITY-TIMI, consisted of the 1863 patients who underwent PCI (median time from randomization 3.2 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/10\">",
"     10",
"    </a>",
"    ]. At 30 days after PCI, clopidogrel therapy was associated with a significant reduction in the primary endpoint of cardiovascular death, MI, or stroke (3.6 versus 6.2 percent, adjusted odds ratio 0.54, 95% CI 0.35-0.85).",
"   </p>",
"   <p>",
"    There are no trials that have examined the efficacy of long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with STEMI. Our authors and reviewers believe that indirect evidence of long-term benefit comes from the PCI-CURE, CREDO, and CURE trials of patients with non-ST elevation ACS, in which clopidogrel was continued for 9 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. There was evidence of increasing benefit over time in these trials (",
"    <a class=\"graphic graphic_figure graphicRef80138 \" href=\"mobipreview.htm?35/49/36637\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53809 \" href=\"mobipreview.htm?19/30/19936\">",
"     figure 4",
"    </a>",
"    ). In addition, a possible benefit from the use of clopidogrel for longer than one year was seen in the CAPRIE trial. This study compared clopidogrel to aspirin (but not the combination) in patients with atherosclerosis not limited to MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/14\">",
"     14",
"    </a>",
"    ]. Clopidogrel therapy significantly reduced the risk of fatal or nonfatal MI; the magnitude of this benefit increased progressively over the three year period of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H16#H16\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some physicians recommend maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    beyond one year or even indefinitely as long as the drug is well tolerated and expense is not an issue. This approach is primarily considered in patients with more severe vascular disease (eg, prior MI or cerebrovascular event or peripheral artery disease) or patients in whom a drug-eluting stent was placed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link&amp;anchor=H1293704686#H1293704686\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514072657\">",
"    <span class=\"h4\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    loading dose of 600 mg instead of 300 mg in STEMI patients undergoing primary PCI (",
"    <a class=\"graphic graphic_table graphicRef73079 \" href=\"mobipreview.htm?27/14/27883\">",
"     table 2",
"    </a>",
"    ), based principally on evidence from the HORIZONS AMI and CURRENT-OASIS 7 trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The best evidence for a dose of 600 mg comes from the CURRENT-OASIS 7 trial, which randomly assigned 25,086 patients with an acute coronary syndrome (29.2 percent STEMI) referred for an invasive strategy to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      600 mg loading dose on day one followed by 150 mg daily for six days and 75 mg thereafter or clopidogrel 300 mg loading dose followed by 75 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/5,16\">",
"       5,16",
"      </a>",
"      ]. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The rate of the primary outcome (cardiovascular death, MI, or stroke at 30 days) was not statistically different (4.2 versus 4.4 percent, respectively) between the two groups. However, in the subgroup of patients who underwent PCI (n = 17,263) the higher dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      significantly reduced the rate of the primary outcome 3.9 versus 4.5 percent; adjusted hazard ratio 0.86, 95% CI 0.74-0.99.",
"     </li>",
"     <li>",
"      The higher dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was associated with a significant reduction in the secondary outcome of definite or probable stent thrombosis among the 17,263 patients who underwent PCI (1.6 versus 2.3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"       \"Antiplatelet therapy after coronary artery stenting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Major bleeding occurred significantly more often in patients who received the higher",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      dose (2.5 versus 2.0 percent in the overall population and 1.6 versus 1.1 in the PCI subgroup).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a subset analysis of the HORIZONS AMI trial, which compared the anticoagulant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      plus GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor, the initial loading dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (300 mg in 1153 patients or 600 mg in 2158 patients) was left to the investigator's discretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/17\">",
"       17",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H14#H14\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Primary PCI'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H27\">",
"       'Evidence in the era of P2Y12 receptor blocker use'",
"      </a>",
"      below). The primary endpoint was a composite of major adverse cardiac events (death from any cause, stroke, reinfarction, and unplanned revascularization for ischemia). After multivariate analysis, the 600 mg dose, compared to 300 mg, was a significant independent predictor of lower rates of major adverse cardiac events (hazard ratio 0.72, 95% CI 0.53-0.98). There was no increase in the rate of major bleeding at the higher dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to our preference for the 600 mg loading dose, we suggest treating patients not at high risk for bleeding for one week with the higher maintenance dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (150 mg) used in the CURRENT-OASIS 7 trial. After one week the maintenance dose is 75 mg daily. A larger discussion of the potential importance of the higher clopidogrel loading dose is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It also seems reasonable to administer dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to the now rare patients who undergo primary PCI without a stent. Subset analysis of the 11 to 18 percent of patients not receiving a stent revealed a significant benefit in PCI-CURE and a nonsignificant trend toward benefit in CREDO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/11,18\">",
"     11,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547672759\">",
"    <span class=\"h3\">",
"     Prasugrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in the TRITON-TIMI 38 trial of 13,608 moderate- to high-risk ACS patients undergoing PCI, including 3534 with STEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/19\">",
"     19",
"    </a>",
"    ]. STEMI patients included 2438 patients with acute STEMI undergoing primary PCI and 1096 patients who had STEMI and were referred for PCI approximately 38 hours post-MI. Patients intended for primary PCI were randomly assigned to either prasugrel or clopidogrel after enrollment (unlike patients with NSTEMI in whom the coronary anatomy had to be known before randomization and study drug administration). Prasugrel was given with a loading dose of 60 mg and maintenance dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    while clopidogrel was given with a 300 mg loading dose and a 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    maintenance dose; the median duration of therapy was 14.5 months. Long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy was recommended in all patients in addition to P2Y12 receptor blocker therapy. The results of this trial need to be viewed in the context of current recommendations for the loading dose of clopidogrel for 600 mg, not 300 mg as used in the trial.",
"   </p>",
"   <p>",
"    The following findings were noted in the group with STEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary efficacy endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke occurred significantly less often in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      at 15 month follow-up (10 versus 12.4 percent; hazard ratio [HR] 0.79; 95% CI 0.65-0.97), driven primarily by a significant reduction in nonfatal MI (7.4 versus 9.7 percent). This benefit was found in patients with either procedure-related or non-procedure related MIs and was seen irrespective of MI size or timing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The rate of definite or probable stent thrombosis (ARC definition) was significantly reduced in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      group (1.6 versus 2.8 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link&amp;anchor=H2#H2\">",
"       \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There was no significant difference in the rate of major bleeding (TIMI) unrelated to coronary artery bypass graft surgery (CABG) at 30 days (hazard ratio 1.11, 95% CI 0.70-1.77).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547672766\">",
"    <span class=\"h3\">",
"     Ticagrelor",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     Ticagrelor",
"    </a>",
"    differs from the thienopyridines (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ) in that it binds reversibly rather than irreversibly with the P2Y12 platelet receptor and has a more rapid onset of action than clopidogrel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/22\">",
"     22",
"    </a>",
"    ]. It has been assigned to a new chemical class of antiplatelet agents, the cyclopentyltriazolopyrimidines. Similar to prasugrel, treatment with ticagrelor leads to more intense platelet inhibition than clopidogrel.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     Ticagrelor",
"    </a>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in over 18,000 ACS patients in the PLATO trial, 38 percent of whom had STEMI with intended PCI. Patients were randomly assigned to ticagrelor 180 mg loading dose followed by 90 mg twice daily or clopidogrel 300 mg loading dose followed by 75 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/6\">",
"     6",
"    </a>",
"    ]. As in the entire cohort of ACS patients, the primary end point (MI, stroke, or cardiovascular death) occurred less often with ticagrelor (9.4 versus 10.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/23\">",
"     23",
"    </a>",
"    ]. There was no significant difference in the rate of non-CABG-related TIMI major bleeding between the ticagrelor and clopidogrel (hazard ratio 1.09, 95% CI 0.80-1.48).",
"   </p>",
"   <p>",
"    The full discussion of the PLATO trial, including outcomes in subgroups, such as those who received higher",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    doses, is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H26#H26\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Ticagrelor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142864574\">",
"    <span class=\"h3\">",
"     Cangrelor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cangrelor is an intravenous P2Y12 receptor blocker that has been compared to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or placebo in three randomized trials which included patients with STEMI and evaluated 48-hour outcomes. These trials are discussed separately. Cangrelor is not approved for use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H9#H9\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Cangrelor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Without reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the use of P2Y12 receptor blocker therapy in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with STEMI who are not reperfused based on the following evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One-half of patients in",
"      <span class=\"nowrap\">",
"       COMMIT/CCS-2,",
"      </span>",
"      which demonstrated benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      therapy, were not reperfused (see",
"      <a class=\"local\" href=\"#H16\">",
"       'With fibrinolytic therapy'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/9,24\">",
"       9,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional support for the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      in patients treated without reperfusion comes from the benefit seen with clopidogrel in patients with a non-ST elevation ACS who were not revascularized in the CURE trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H16#H16\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Clopidogrel'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514073031\">",
"    <span class=\"h2\">",
"     Bleeding risk and early CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to concerns about bleeding at the time of coronary artery bypass graft surgery, our authors and reviewers recommend stopping the P2Y12 receptor blocker (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should be continued) in most patients for whom a decision has been made to perform CABG after STEMI. Discontinuation for approximately five days allows for the antiplatelet effect of the drug to wash out.",
"   </p>",
"   <p>",
"    The likelihood of life-threatening or major bleeding within seven days of CABG was non-significantly increased in patients in the CURE trial who had received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    within the five days prior to CABG (9.6 versus 6.3 percent with placebo), but not in those who had discontinued clopidogrel &ge;5 days prior to CABG (4.4 versus 5.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/25\">",
"     25",
"    </a>",
"    ]. This finding is supported by several observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H8#H8\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the TRITON-TIMI 38 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/19\">",
"     19",
"    </a>",
"    ] and PLATO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/6\">",
"     6",
"    </a>",
"    ] trials of P2Y12 receptor blocker therapy, the risk of CABG related major bleeding was significantly increased with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    (13.4 versus 3.2 percent) but not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    (7.4 versus 7.9 percent) compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H22#H22\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Prasugrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H26#H26\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Ticagrelor'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Although we recommend stopping P2Y12 receptor blocker prior to CABG in most patients, any excess bleeding risk due to recent P2Y12 receptor blocker use in the minority of patients who will or might require early CABG must be weighed against the potentially deleterious effect of delaying or not administering such therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/31\">",
"     31",
"    </a>",
"    ]. In subgroup analyses of the ACUITY and CURE trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/25,32\">",
"     25,32",
"    </a>",
"    ], patients with ACS who underwent CABG who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    had a lower rate of adverse outcomes than those who did not. For instance, in ACUITY, the rate of the primary composite outcome at 30 days was significantly less in those who received clopidogrel compared to those who did not (12.7 versus 17.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link&amp;anchor=H33#H33\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514073332\">",
"    <span class=\"h2\">",
"     Non-bleeding adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three important nonbleeding side effects of P2Y12 receptor blocker use have been identified: neutropenia and thrombotic thrombocytopenia",
"    <span class=\"nowrap\">",
"     purpura/hemolytic",
"    </span>",
"    uremic syndrome (TTP-HUS), both of which are primarily described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , and hypersensitivity, which is more common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554043015\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no trials that compare different durations of dual antiplatelet therapy in patients with acute coronary syndromes. Based on the CURE, TRITON&ndash;TIMI 38, and PLATO trials, which continued dual antiplatelet therapy for at least 12 months, we recommend this a the minimum duration of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for the use of antiplatelet therapy in patient with STEMI are summarized in two tables (",
"    <a class=\"graphic graphic_table graphicRef75032 \" href=\"mobipreview.htm?33/25/34206\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73079 \" href=\"mobipreview.htm?27/14/27883\">",
"     table 2",
"    </a>",
"    ). Outcomes after STEMI are better with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus P2Y12 receptor blocker than with aspirin alone, irrespective of whether patients are managed with primary PCI, fibrinolysis, or medical therapy. In addition, evidence from TRITON-TIMI 38 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ) and PLATO (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ) provides strong support for the general idea that agents with higher levels of platelet inhibition have lower cardiovascular event rates but higher rates of bleeding compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dual antiplatelet therapy should be given as soon as possible after diagnosis. However, in circumstances in which coronary artery bypass surgery might be necessary and the cardiothoracic surgical team is uncomfortable operating on patients taking dual antiplatelet therapy, it is reasonable to defer giving these drugs until after angiography. In these patients, the early initiation of a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor may be useful.",
"   </p>",
"   <p>",
"    As the trials presented above vary somewhat in timing of initiation of P2Y12 receptor blocker therapy and whether patients were treated with an invasive or conservative strategy, our recommendations vary based on the management strategy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients treated with medical therapy (no revascularization), we prefer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       Prasugrel",
"      </a>",
"      has not been studied in these patients.",
"     </li>",
"     <li>",
"      For patients managed with primary PCI, we prefer either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (given at presentation) to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      . When clopidogrel is chosen, we suggest treating patients not at high risk for bleeding for one week with a higher maintenance dose of clopidogrel (150 mg) when clopidogrel is chosen. After one week the maintenance dose of clopidogrel is 75 mg daily.",
"     </li>",
"     <li>",
"      For patients managed with fibrinolytic therapy, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      , as these latter two have not been tested in this setting. There are no data regarding safety and bleeding risk with prasugrel or ticagrelor combined with fibrinolytic therapy. If a STEMI patient treated with fibrinolytic therapy is later referred for PCI, use of prasugrel is reasonable; in the TRITON-TIMI 38 trial, prasugrel led to better outcomes than clopidogrel.",
"     </li>",
"     <li>",
"      Our recommendations for the loading dose of the P2Y12 agents in STEMI are summarized in a table (",
"      <a class=\"graphic graphic_table graphicRef73079 \" href=\"mobipreview.htm?27/14/27883\">",
"       table 2",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      The maintenance doses are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75 mg daily,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      10 mg daily, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      90 mg twice daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend that dual antiplatelet therapy be continued for at least one year.",
"   </p>",
"   <p>",
"    Issues of cost or availability may influence the choice of one of the three P2Y12 receptor blockers.",
"   </p>",
"   <p>",
"    <br/>",
"    The issue of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    reloading is discussed separately. (See",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H7#H7\">",
"      \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Patients already taking clopidogrel'",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514072637\">",
"    <span class=\"h1\">",
"     RESISTANCE/NONRESPONSE TO ASPIRIN OR CLOPIDOGREL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance/nonresponse",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , along with methods to determine in vitro platelet function following treatment with clopidogrel, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     GLYCOPROTEIN IIb/IIIa INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiplatelet potency of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is relatively limited, because it inhibits only one of several important pathways to platelet activation and aggregation. Thus, the addition of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor may be of benefit. Evidence of benefit for the use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in many patients with STEMI has came in large part from randomized trials performed prior to the routine use of dual (oral) antiplatelet therapy (DAPT). Among patients with an STEMI, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors have primarily been evaluated as adjunctive therapy in patients undergoing coronary reperfusion with either primary PCI or fibrinolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Use in primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the trials that compared GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors to placebo enrolled STEMI patients before the use of P2Y12 inhibitors became routine. As these drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    in particular) are potent inhibitors of platelet aggregation, it is possible that there is little incremental benefit from GP",
"    <span class=\"nowrap\">",
"     IIb/III",
"    </span>",
"    inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Evidence prior to the routine use of P2Y12 receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supports the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    in patients with STEMI undergoing primary PCI with either balloon angioplasty or stenting and receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (but not being pretreated with a P2Y12 inhibitor). A meta-analysis of over 27,000 patients in eleven trials found that abciximab, compared to placebo, significantly lowered the rate of death at 30 days (2.4 versus 3.4 percent; odds ratio 0.68, 95% CI 0.47-0.99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/33\">",
"     33",
"    </a>",
"    ]. Evidence of benefit from either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    in this setting is less convincing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link&amp;anchor=H10#H10\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\", section on 'ACS patients undergoing PTCA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link&amp;anchor=H9300137#H9300137\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\", section on 'STEMI patients undergoing PCI with stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This evidence provides support for a recommendation for the early use of a",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    inhibitor in patients not treated with a P2Y12 receptor blocker before PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Evidence in the era of P2Y12 receptor blocker use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above discussion supports the use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, and in particular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    , in patients with STEMI who undergo primary PCI and are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH), but not pretreated with a P2Y12 receptor blocker.",
"   </p>",
"   <p>",
"    Two trials, On-TIME 2 and BRAVE-3, compared intravenous GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors to placebo in patients pretreated with P2Y12 receptor blockers (and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) and who received anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The first trial suggested benefit while the latter did not. However, as we prefer anticoagulation with bivalirudin as opposed to heparin in patients undergoing primary PCI based on the HORIZONS AMI trial, the findings from these two trials are less relevant to decision making. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H21647881#H21647881\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HORIZONS AMI provided evidence to support a recommendation to not generally use GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in STEMI patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    . The role of intracoronary GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in these patients was evaluated in the INFUSE-AMI trial. In this study, 452 individuals (treated with bivalirudin) with left anterior descending artery (LAD) coronary artery occlusion were randomly assigned in a 2X2 factorial design to bolus intracoronary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    or no abciximab and to manual aspiration thrombectomy or no thrombectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/36\">",
"     36",
"    </a>",
"    ]. At 30 days there was a small but significant reduction in infarct size (the percentage of total left ventricular mass assessed by cardiac magnetic resonance imaging) comparing intracoronary abciximab to no abciximab (15.1 versus 17.9 percent). Limitations of INFUSE-AMI include its small sample size, the small magnitude of infarct-size reduction, nonclinical end point, and the fact that there was no imputation for infarct size among patients with missing data, such as those who died. The discussion of the role of aspiration thrombectomy in acute STEMI is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H9#H9\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'Thrombectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy prior to primary PCI improves outcomes, compared with placebo, in STEMI patients not treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    or preloading of a P2Y12 inhibitor. In patients treated with high-dose preloading of a P2Y12 receptor blocker the evidence is less clear. Further evidence regarding the potential benefit of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in STEMI patients undergoing primary PCI comes from trials comparing early to late use.",
"   </p>",
"   <p>",
"    A 2006 meta-analysis of nine trials with over 1100 patients concluded that PCI after the administration of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in the ambulance or emergency department, rather than in the catheterization laboratory, was associated with a significant increase in initial TIMI 3 (normal) flow (26 versus 15 percent), but",
"    <strong>",
"     no",
"    </strong>",
"    difference in either final TIMI 3 flow after PCI (90 versus 85 percent) or in major clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evidence against clinical benefit from early GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy compared to use in the catheterization laboratory comes from the FINESSE trial, which was concluded after the meta-analysis. In FINESSE, 2452 patients were randomly assigned to one of three regimens: the early administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    and reduced dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    prior to PCI, early administration of abciximab alone, or abciximab given at the time of PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/38\">",
"     38",
"    </a>",
"    ]. All patients received unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    before PCI and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was given in most patients who received stenting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There was no significant difference between the three treatment groups in the composite primary endpoint of death from all causes, ventricular fibrillation occurring more than 48 hours after randomization, cardiogenic shock, and heart failure at 90 days. However, there was a significant increase in TIMI major and minor bleeding in the group that received early administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    , compared to the group that received abciximab at the time or primary PCI (10.1 versus 6.9 percent).",
"   </p>",
"   <p>",
"    The above evidence provides no evidence of benefit from pretreatment with GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors prior to primary PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24452201\">",
"    <span class=\"h3\">",
"     Intravenous versus intracoronary delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors have been given by the intravenous or intracoronary route in patients with STEMI. Studies evaluating end points such as infarct size or markers of reperfusion have found intracoronary administration more effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/39\">",
"     39",
"    </a>",
"    ]. Two relatively small meta-analyses of heterogenous randomized trials found an approximately 50 percent relative reduction in early mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, the two meta-analyses did not include the largest randomized trial, AIDA STEMI.",
"   </p>",
"   <p>",
"    AIDA STEMI randomly assigned 2065 patients undergoing primary PCI (and who were treated with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as well as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker) to either intracoronary or intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    during PCI (both followed by a 12-hour infusion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/42\">",
"     42",
"    </a>",
"    ]. There was no significant difference between the two groups in the rate of the primary composite outcome of all-cause mortality, recurrent infarction, or new congestive heart failure within 90 days of randomization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of primary PCI,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    is the best studied GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. While no large head-to-head, randomized comparisons of major adverse cardiovascular outcomes using these agents have been performed, available data from small randomized trials with surrogate endpoints and from observational studies suggests equivalent efficacy among abciximab,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/45-50\">",
"     45-50",
"    </a>",
"    ]. The best available evidence is summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MULTISTRATEGY and EVA-AMI randomized trials compared either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      (n = 745) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      (n = 427), respectively to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      for the surrogate endpoint of early ST-segment resolution, a measure of myocardial reperfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/46,49\">",
"       46,49",
"      </a>",
"      ]. In both trials, non-inferiority of either tirofiban or eptifibatide was observed.",
"     </li>",
"     <li>",
"      The SCAAR registry was used to compare outcomes in over 11,000 STEMI patients who underwent primary PCI and received either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/50\">",
"       50",
"      </a>",
"      ]. The primary combined endpoint of death or MI during one year follow-up occurred in 15.0 and 15.7 percent of patients respectively, a difference that was not significantly different and represented proof of non-inferiority (of eptifibatide). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=see_link\">",
"       \"Drug-eluting intracoronary stents: General principles\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1465590544\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing regimens for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    for patients with STEMI are based on dosing regimens used in clinical trials. The duration of therapy depends on the agent selected, and is 12 hours for abciximab and 18 to 24 hours for eptifibatide or tirofiban:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       Abciximab",
"      </a>",
"      &mdash;A bolus of 0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      should be followed by a continuous infusion of 0.125",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"      (maximum: 10",
"      <span class=\"nowrap\">",
"       mcg/min),",
"      </span>",
"      which is continued for 12 hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       Eptifibatide",
"      </a>",
"      &mdash;A loading dose of 180",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      (maximum: 22.6 mg) over one to two minutes, should be followed by a continuous infusion of 2",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"      (maximum: 15",
"      <span class=\"nowrap\">",
"       mg/hour),",
"      </span>",
"      which is continued for 18 to 24 hours. A second",
"      <span class=\"nowrap\">",
"       180-mcg/kg",
"      </span>",
"      bolus should be given 10 minutes after the first bolus.",
"      <br/>",
"      <br/>",
"      The continuous infusion should be reduced by 50 percent in patients with estimated creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       Tirofiban",
"      </a>",
"      &mdash;A loading dose of 25",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      (referred to as the high-bolus dose) over three minutes, which should be followed by a continuous infusion of 0.15",
"      <span class=\"nowrap\">",
"       mcg/kg/min,",
"      </span>",
"      which is continued for 18 to 24 hours. This dosing is not in United States (US) licensed product information (the US approved dose is 0.4",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"      over 30 minutes and infusion of 0.1",
"      <span class=\"nowrap\">",
"       mcg/kg/min).",
"      </span>",
"      This higher dose of tirofiban has shown benefit in small studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/51,52\">",
"       51,52",
"      </a>",
"      ] and is in the licensed product information for the United Kingdom and some European countries, but has not been validated in large clinical trials. We are concerned that any lower dose will not achieve adequate GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor blocked if given soon before PCI. The optimal dose for patients not undergoing PCI within four hours is unknown, but the US approved dose may achieve adequate platelet inhibition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/53-55\">",
"       53-55",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If tirofiban is chosen, we suggest that the infusion dose reduced by 50 percent in patients with an estimated creatinine clearance of &lt;30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence discussed above leaves substantial uncertainty regarding the balance of benefit and risk of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors during primary PCI for STEMI in the context of other contemporary antithrombotic therapies, including P2Y12 blockers and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    . Recognizing these uncertainties, we suggest the following guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We prefer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"      </a>",
"      ) rather than unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (UFH) in patients undergoing primary PCI. If bivalirudin is chosen, we suggest not routinely using a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor and using it provisionally for ischemic or angiographic complications or heavy intracoronary thrombus burden during PCI. A P2Y12 receptor blocker should be administered prior to PCI, particularly if bivalirudin without routine GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      blockade is chosen.",
"     </li>",
"     <li>",
"      If UFH is chosen as the anticoagulant during PCI for STEMI, we suggest using a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor, unless the patient is at high risk for bleeding. We recommend a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor with UFH if a P2Y12 blocker is not administered prior to PCI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the available evidence, we believe that either the intravenous or intracoronary route is reasonable for those STEMI patients in whom a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor will be used. However, the intracoronary route is not licensed by the United States Food and Drug Administration or the European Medicines Agency (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    ) or member European Union countries (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Our authors and reviewers have differing preferences regarding the choice of intravenous agent, with some choosing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    due to its demonstrated efficacy in multiple trials, while others choosing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    or high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    for cost reasons as well as a belief that outcomes are similar between agents.",
"   </p>",
"   <p>",
"    In addition, intracoronary GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor may be a reasonable additional antiplatelet therapy in patients with acute occlusion of the left anterior descending coronary artery. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Evidence in the era of P2Y12 receptor blocker use'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Use with a fibrinolytic agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy using a half-dose of a fibrinolytic agent with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor had been hypothesized to be more likely to restore coronary perfusion, promote ST segment resolution at 90 minutes, and reduce the incidence of recurrent ischemia, nonfatal reinfarction, and rescue PCI. However, two large trials, GUSTO V and ASSENT-3, and a meta-analysis cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/33\">",
"     33",
"    </a>",
"    ], found no improvement in survival compared to conventional fibrinolytic therapy, and bleeding was increased, particularly in patients over age 75. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14778?source=see_link&amp;anchor=H23#H23\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\", section on 'GP IIb/IIIa inhibitors and reduced dose fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend use of half-dose fibrinolytic therapy plus a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor as a primary reperfusion regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/43,56\">",
"     43,56",
"    </a>",
"    ]. There is no evidence to support the use of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in patients receiving full-dose fibrinolytic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Use without reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with acute STEMI do not undergo reperfusion therapy, usually because of late presentation, absence of ST segment elevation at presentation, or lack of availability of a catheterization laboratory. The TETAMI trial, which evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    compared to placebo in such patients, found no evidence of benefit from tirofiban [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend the use of GP",
"    <span class=\"nowrap\">",
"     IIb/III",
"    </span>",
"    inhibitors in STEMI patients who do not receive reperfusion therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514073968\">",
"    <span class=\"h2\">",
"     Bleeding risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major bleeding can occur after the administration of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor as a consequence of inhibition of platelet function or thrombocytopenia. The mechanism and frequency of thrombocytopenia, as well as recommendations for measurement of platelet count, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24918?source=see_link\">",
"     \"Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In randomized, placebo-controlled clinical trials of the GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    had a 0 to 7 percent excess risk of major bleeding compared to placebo, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    had a 0 to 2 percent excess risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    .) Rates of major bleeding with GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors were reduced in trials using low-dose, weight-adjusted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (50-70",
"    <span class=\"nowrap\">",
"     U/kg).",
"    </span>",
"   </p>",
"   <p>",
"    However, many of these trials were completed before the stent era in which the administration of both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    has become routine. Data on the rates of major bleeding in patients with STEMI treated with aspirin, P2Y12 inhibitor and a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor are limited. We believe it is reasonable to assume rates would be similar to patients with non-ST elevation ACS treated with similar regimes. The best available data comes from the ISAR-REACT 2 trial and the CRUSADE initiative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In ISAR-REACT 2, a study of unstable",
"      <span class=\"nowrap\">",
"       angina/non-ST",
"      </span>",
"      elevation MI patients, all patients received pretreatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and 600 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/58\">",
"       58",
"      </a>",
"      ]. The rates of major bleeding for patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      or placebo were not significantly different (4.5 and 4.0, respectively).",
"     </li>",
"     <li>",
"      In an analysis of 32,600 patients with a non-ST elevation ACS in the nonrandomized CRUSADE initiative, the rate of major bleeding, defined as a drop in hematocrit of &ge;12 percent, need for transfusion, or intracranial hemorrhage, was significantly higher in patients who received GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors (10.1 versus 6.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/59\">",
"       59",
"      </a>",
"      ]. Some of this increase in risk may have been due to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , since the rate of clopidogrel use was higher in the patients treated with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor (63 versus 39 percent in those who did not receive a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsets of patients at increased risk for GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa-induced",
"    </span>",
"    major bleeding have been identified, including those with moderate to severe renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/62\">",
"     62",
"    </a>",
"    ], and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/59\">",
"     59",
"    </a>",
"    ]. The use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in elderly patients and women requires careful weight and renal function-based dose adjustment, and should be limited to circumstances when GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    drugs are clearly needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another concern is the possible need for emergency coronary artery bypass graft surgery (CABG) after the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    , although this should not be considered a contraindication to such surgery. One report evaluated surgical outcomes in 85 patients in the EPILOG and EPISTENT trials who required emergency CABG after abciximab therapy associated with PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/64\">",
"     64",
"    </a>",
"    ]. These patients, compared to those not treated with abciximab, had no significant increase in major blood loss or red cell transfusion and no reduction in the use of optimal mammary artery grafts. However, abciximab-treated patients were more likely to require surgical reexploration for bleeding (12 versus 3 percent). The use of intraoperative ACT-guided",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dosing and selective application of platelet transfusions are appropriate in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514072412\">",
"    <span class=\"h1\">",
"     PATIENTS TAKING ORAL ANTICOAGULANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , as well as both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , is necessary in some patients with STEMI, such as those with atrial fibrillation, left ventricular mural thrombus, prosthetic heart valves, or deep vein thrombosis. In such patients, the risk of bleeding complications is increased compared to either warfarin or dual antiplatelet therapy alone. The recommended INR in this setting is 2.0 to 2.5, and close monitoring is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=see_link\">",
"     \"Chronic anticoagulation after acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H241541639\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of active gastrointestinal bleeding presents a challenge to the care of the patient with ACS. The discussion of the incidence, risk factors, outcomes, prevention, and treatment of periprocedural gastrointestinal bleeding is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514072443\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the management of patients with STEMI have been published by the European Society of Cardiology (2012), the American College of Cardiology Foundation(ACCF)",
"    <span class=\"nowrap\">",
"     /American",
"    </span>",
"    Heart Association (AHA) (2013), and the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/49/35610/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no major differences between recommendations made in this topic review and in these guidelines, with one exception. We prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in patients undergoing percutaneous coronary intervention, while the 2013",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    guideline considers all three equivalent and the 2012 ACCP guideline makes a weak recommendation to prefer ticagrelor over clopidogrel (but doesn&rsquo;t specify a preference for prasugrel over clopidogrel). (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Summary'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is strong evidence to support the early initiation of dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker, irrespective of treatment strategy (fibrinolysis, primary percutaneous coronary intervention [PCI], or medical therapy), in patients with acute ST-elevation myocardial infarction (STEMI). The evidence is less strong to support the use of intravenous GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy in patients with planned primary PCI, and none in patients receiving fibrinolytic therapy or no reperfusion.",
"   </p>",
"   <p>",
"    Our recommendations for the early use of antiplatelet therapy in patients with STEMI follow; recommendations for the long-term use of these drugs are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H611367206#H611367206\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Secondary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185089155\">",
"    <span class=\"h2\">",
"     All patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus a platelet P2Y12 receptor blocker as soon as possible after presentation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Aspirin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Summary'",
"      </a>",
"      above). The first aspirin tablet should contain 162 to 325 mg and be chewed. The suggested maintenance dose of aspirin is 75 to 162",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      unless",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      is used, in which case the dose should be 75 to 100",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We recommend aspirin and a platelet P2Y12 receptor blocker for a minimum of one year (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H19#H19\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Duration of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For those patients with a history of gastrointestinal bleeding, drugs that reduce the risk of recurrent bleeding (eg, proton pump inhibitors) should be given.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link&amp;anchor=H5971648#H5971648\">",
"       \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169940262\">",
"    <span class=\"h2\">",
"     Fibrinolytic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving fibrinolytic therapy, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      in preference to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Neither the efficacy nor the safety of ticagrelor or prasugrel in conjunction with fibrinolytic therapy has been evaluated and there is a potential for life threatening bleeding (eg, intracranial hemorrhage). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'With fibrinolytic therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The suggested loading dose of clopidogrel is 300 mg for those who are less than 75 years of age. For patients 75 years of age or older, clopidogrel 75 mg should be given (",
"      <a class=\"graphic graphic_table graphicRef73079 \" href=\"mobipreview.htm?27/14/27883\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169940271\">",
"    <span class=\"h2\">",
"     Planned primary PCI",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with planned primary PCI, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      in preference to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The loading dose for ticagrelor is 180 mg and for prasugrel is 60 mg (",
"      <a class=\"graphic graphic_table graphicRef73079 \" href=\"mobipreview.htm?27/14/27883\">",
"       table 2",
"      </a>",
"      ). Prasugrel is contraindicated in patients with prior stroke or transient ischemic attack, or those with active pathological bleeding. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'With primary PCI'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For those patients in whom clopidogrel is chosen, we recommend a loading dose of 600 mg as opposed to 300 mg (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest treating PCI patients not at high risk for bleeding for one week with clopidogrel 150 mg daily and then reducing the dose to 75 mg daily. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Summary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients not at high risk of bleeding in whom",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is chosen as the anticoagulant and who receive a P2Y12 receptor blocker prior to PCI, we suggest the addition of a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor, as opposed to not adding this antiplatelet agent, after diagnostic angiography (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For those patients at high risk of bleeding who are treated with heparin, the risks and benefits of adding a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor will need to be weighed.",
"      <br/>",
"      <br/>",
"      For patients treated with heparin who do not receive a P2Y12 receptor blocker prior to PCI, we recommend the addition of a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor, as opposed to not adding this agent, after diagnostic angiography (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Our authors and reviewers have differing preferences for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      in this setting. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Use in primary PCI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      , we suggest not routinely adding GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H21647881#H21647881\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Bivalirudin'",
"      </a>",
"      .) For these patients with a left anterior descending coronary artery lesion or ischemic or angiographic complications or heavy intracoronary thrombus burden during PCI, the addition of a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor is reasonable.",
"     </li>",
"     <li>",
"      For patients who will not be receiving early P2Y12 therapy due to a concern for a need for urgent coronary artery bypass surgery, we recommend addition of a glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In this setting, we prefer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169940279\">",
"    <span class=\"h2\">",
"     No reperfusion therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving neither fibrinolytic therapy nor primary percutaneous coronary intervention, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      in preference to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Without reperfusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/1\">",
"      Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/2\">",
"      Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/3\">",
"      Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/4\">",
"      Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/5\">",
"      CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/6\">",
"      Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/7\">",
"      Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:670S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/8\">",
"      Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179.",
"     </a>",
"    </li>",
"    <li>",
"     www.commit-ccs2.org (Accessed on March 24, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/10\">",
"      Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/11\">",
"      Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/12\">",
"      Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/13\">",
"      Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/14\">",
"      CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/15\">",
"      Cannon CP, CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002; 90:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/16\">",
"      Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/17\">",
"      Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009; 54:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/18\">",
"      Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/19\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/20\">",
"      Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/21\">",
"      Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009; 119:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/22\">",
"      Sch&ouml;mig A. Ticagrelor--is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009; 361:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/23\">",
"      Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/24\">",
"      Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/25\">",
"      Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/26\">",
"      Chu MW, Wilson SR, Novick RJ, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004; 78:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/27\">",
"      Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/28\">",
"      Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2006; 48:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/29\">",
"      Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/30\">",
"      Kim JH, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008; 156:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/31\">",
"      Bavry AA, Lincoff AM. Is clopidogrel cardiovascular medicine's double-edged sword? Circulation 2006; 113:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/32\">",
"      Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2009; 53:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/33\">",
"      De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/34\">",
"      ten Berg JM, van 't Hof AW, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol 2010; 55:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/35\">",
"      Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009; 119:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/36\">",
"      Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012; 307:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/37\">",
"      Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/38\">",
"      Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/39\">",
"      Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010; 122:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/40\">",
"      Shimada YJ, Nakra NC, Fox JT, Kanei Y. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2012; 109:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/41\">",
"      Wang Y, Wu B, Shu X. Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction. Am J Cardiol 2012; 109:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/42\">",
"      Thiele H, W&ouml;hrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 2012; 379:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/43\">",
"      Goodman SG, Menon V, Cannon CP, et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:708S.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/45\">",
"      Raveendran G, Ting HH, Best PJ, et al. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction. Mayo Clin Proc 2007; 82:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/46\">",
"      Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008; 299:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/47\">",
"      Gurm HS, Smith DE, Collins JS, et al. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 2008; 51:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/48\">",
"      De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 2009; 53:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/49\">",
"      Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. J Am Coll Cardiol 2010; 56:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/50\">",
"      Akerblom A, James SK, Koutouzis M, et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol 2010; 56:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/51\">",
"      van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs 2009; 69:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/52\">",
"      Schneider DJ, Herrmann HC, Lakkis N, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002; 90:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/53\">",
"      A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/54\">",
"      Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/55\">",
"      Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006; 47:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/56\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/57\">",
"      Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003; 42:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/58\">",
"      Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/59\">",
"      Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 2006; 114:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/60\">",
"      Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/61\">",
"      Best PJ, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003; 146:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/62\">",
"      Sadeghi HM, Grines CL, Chandra HR, et al. Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile. J Am Coll Cardiol 2003; 42:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/63\">",
"      Melloni C, Peterson ED, Chen AY, et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2008; 51:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/64\">",
"      Lincoff AM, LeNarz LA, Despotis GJ, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. Ann Thorac Surg 2000; 70:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/65\">",
"      Juergens CP, Yeung AC, Oesterle SN. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol 1997; 80:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/66\">",
"      Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/67\">",
"      Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/68\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/69\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/49/35610/abstract/70\">",
"      Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 94 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.147-71980919F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35610=[""].join("\n");
var outline_f34_49_35610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION OF ANTIPLATELET AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evidence of benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      P2Y12 RECEPTOR BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      With fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      With primary PCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H547672752\">",
"      - Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H514072657\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H547672759\">",
"      - Prasugrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H547672766\">",
"      - Ticagrelor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1142864574\">",
"      - Cangrelor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Without reperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H514073031\">",
"      Bleeding risk and early CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H514073332\">",
"      Non-bleeding adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1554043015\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H514072637\">",
"      RESISTANCE/NONRESPONSE TO ASPIRIN OR CLOPIDOGREL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      GLYCOPROTEIN IIb/IIIa INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Use in primary PCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Evidence prior to the routine use of P2Y12 receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Evidence in the era of P2Y12 receptor blocker use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24452201\">",
"      - Intravenous versus intracoronary delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1465590544\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Use with a fibrinolytic agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Use without reperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H514073968\">",
"      Bleeding risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H514072412\">",
"      PATIENTS TAKING ORAL ANTICOAGULANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H241541639\">",
"      GASTROINTESTINAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H514072443\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H185089155\">",
"      All patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169940262\">",
"      Fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169940271\">",
"      Planned primary PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169940279\">",
"      No reperfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/94\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/94|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/48/29440\" title=\"figure 1\">",
"      Mechanism antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/29/34269\" title=\"figure 2\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/49/36637\" title=\"figure 3\">",
"      Clopidogrel in CREDO one year",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/30/19936\" title=\"figure 4\">",
"      Benefit clopidogrel over time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/94|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/34/43564\" title=\"table 1\">",
"      Effect of antiplatelet therapy on vascular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/14/27883\" title=\"table 2\">",
"      Platelet P2Y12 receptor blocker loading doses in acute STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/25/34206\" title=\"table 3\">",
"      Rapid overview ACS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=related_link\">",
"      Chronic anticoagulation after acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3594?source=related_link\">",
"      Effect of cardiac drugs on platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=related_link\">",
"      Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4167?source=related_link\">",
"      The role of platelets in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24918?source=related_link\">",
"      Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_49_35611="Treatment studies BV preg";
var content_f34_49_35611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment regimens used in studies demonstrating a reduction in preterm birth in treated high risk patients with bacterial vaginosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Metronidazole 400 mg orally twice daily for two consecutive days. Repeat if a second test four weeks post-treatment is positive.",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metronidazole 250 mg orally three times daily for seven days plus erythromycin base 333 mg orally&nbsp;three times daily for 14 days. Repeat test at 28 weeks of gestation and repeat treatment if test is positive.",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metronidazole 250 mg orally three times daily for seven days. No second treatment.",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin 300 mg orally twice daily for five days. No second treatment.",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin 5 grams of 2 percent vaginal cream nightly for three nights. Repeat test three weeks after initial diagnosis, if still positive give a seven day course of the the same treatment.",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        McDonald, HM, O'Loughlin, JA, Vigneswaran, R, et al. Br J Obstet Gynaecol 1997; 104:1391.",
"       </li>",
"       <li>",
"        Hauth, JC, Goldenberg, RL, Andrews, WW, et al. N Engl J Med 1995; 333:1732.",
"       </li>",
"       <li>",
"        Morales, WJ, Schorr, S, Albritton, J. Am J Obstet Gynecol 1994; 171:345.",
"       </li>",
"       <li>",
"        Ugwumadu, A, Manyonda, I, Reid, F, Hay, P. Lancet 2003; 361:983.",
"       </li>",
"       <li>",
"        Lamont, RF, Duncan, SL, Mandal, D, Bassett, P. Obstet Gynecol 2003; 101:516.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35611=[""].join("\n");
var outline_f34_49_35611=null;
var title_f34_49_35612="Incision and drainage procedure";
var content_f34_49_35612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Procedure summary: Incision and drainage of skin abscess",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Explain the procedure to the patient and/or caretaker and obtain informed consent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Provide prophylaxis for bacterial endocarditis, if indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Provide procedural sedation and analgesia in addition to local anesthesia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Incision and drainage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Identify the area of maximal fluctuance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Using a scalpel with either an 11 or 15 blade, make a simple linear incision at the point of maximal fluctuance and through the length of the abscess; a stab incision may be used in a cosmetic area.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Obtain culture of drainage fluid, if indicated*.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Bluntly probe the abscess cavity with a curved hemostat to remove any identified foreign body and to break up loculations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Copiously irrigate the abscess cavity with normal saline until all visible pus is removed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Pack large abscesses (&gt;5 cm in diameter) and pilonidal abscesses with sterile packing gauze or iodoform. Some physicians may choose to pack all abscesses that will accept packing strips.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. We suggest that abscesses be left open to heal by secondary intention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Provide antibiotic therapy to selected patients",
"        <sup>",
"         &bull;",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Provide tetanus prophylaxis, as indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Schedule the patient for a wound check within 24 to 48 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. At the follow-up visit, remove packing (if present) in patients whose drainage has stopped and initiate warm wet soaks (mild saline solution or soapy water).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. If drainage persists at the follow-up visit, remove the old packing material and repack with new packing strips. Continue evaluation every 24 to 48 hours with repacking until the drainage stops.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. If the patient underwent primary closure, remove sutures if pus has reaccumulated. Otherwise, instruct the patient to keep the wound clean and arrange for suture removal seven days after initial incision and drainage.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * We suggest that wound cultures of abscess drainage be obtained in all patients who will be treated with antibiotics to guide further therapy in the event that the abscess progresses or recurs and to provide monitoring for the prevention and control of MRSA infection, especially in immunocompromised and hospitalized patients.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     We suggest that patients with multiple lesions, extensive surrounding cellulitis, immunosuppression, risk for MRSA or systemic signs of infection be managed with incision and drainage as well as antimicrobial therapy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35612=[""].join("\n");
var outline_f34_49_35612=null;
var title_f34_49_35613="Dermoscopy sensitivity and specificity";
var content_f34_49_35613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity for melanoma diagnosis of different dermoscopic algorithms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Algorithm/method",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Sensitivity (percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Specificity (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Amelanotic melanoma",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pigmented melanoma",
"       </td>",
"       <td class=\"subtitle2\">",
"        Experts",
"       </td>",
"       <td class=\"subtitle2\">",
"        Non-experts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        <strong>",
"         Quantitative",
"        </strong>",
"       </td>",
"       <td>",
"        ABCD Rule",
"        <sup>",
"         [1-8]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        78-98",
"       </td>",
"       <td class=\"centered\">",
"        70-90",
"       </td>",
"       <td class=\"centered\">",
"        45-80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Menzies Method",
"        <sup>",
"         [1,3,4,7,9,10]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        54",
"       </td>",
"       <td class=\"centered\">",
"        86-95",
"       </td>",
"       <td class=\"centered\">",
"        71-78",
"       </td>",
"       <td class=\"centered\">",
"        38-76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7-point checklist",
"        <sup>",
"         [1-5,7,9,11-13]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        41",
"       </td>",
"       <td class=\"centered\">",
"        62-95",
"       </td>",
"       <td class=\"centered\">",
"        71-87",
"       </td>",
"       <td class=\"centered\">",
"        35-97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Revised 7-point checklist",
"        <sup>",
"         [13]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        88",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-point checklist",
"        <sup>",
"         [9,14,15]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        79-91",
"       </td>",
"       <td class=\"centered\">",
"        71-72",
"       </td>",
"       <td class=\"centered\">",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CASH algorithm",
"        <sup>",
"         [3,16]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        87-98",
"       </td>",
"       <td class=\"centered\">",
"        68",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Qualitative",
"        </strong>",
"       </td>",
"       <td>",
"        Pattern analysis",
"        <sup>",
"         [1,2,5,7,13]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        82-85",
"       </td>",
"       <td class=\"centered\">",
"        79-88",
"       </td>",
"       <td class=\"centered\">",
"        61-79",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Argenziano G, Soyer H, Chimenti S, et al, Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.",
"       </li>",
"       <li>",
"        Annessi G, Bono R, Sampogna F, et al. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol 2007; 56:759.",
"       </li>",
"       <li>",
"        Henning JS, Stein JA, Yeung J, et al. CASH algorithm for dermoscopy revisited. Arch Dermatol 2008; 144:554.",
"       </li>",
"       <li>",
"        Blum A, Rassner G, Garbe C. Modified ABC-point list of dermoscopy: A simplified and highly accurate dermoscopic algorithm for the diagnosis of cutaneous melanocytic lesions. J Am Acad Dermatol 2003; 48:672.",
"       </li>",
"       <li>",
"        Carli P, Quercioli E, Sestini S, et al. Pattern analysis, not simplified algorithms, is the most reliable method for teaching dermoscopy for melanoma diagnosis to residents in dermatology. Br J Dermatol 2003; 148:981.",
"       </li>",
"       <li>",
"        Stolz W, Riemann A, Cognetta A, et al. ABCD rule of dermoscopy: a new practical method for early recognition of maligant melanoma. Eur J Dermatol 1994; 4:521.",
"       </li>",
"       <li>",
"        Pagnanelli G, Soyer HP, Argenziano G, et al. Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts. Br J Dermatol 2003; 148:698.",
"       </li>",
"       <li>",
"        Dolianitis C, Kelly J, Wolfe R, Simpson P. Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions. Arch Dermatol 2005; 141:1008.",
"       </li>",
"       <li>",
"        Menzies SW, Kreusch J, Byth K, et al. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol 2008; 144:1120.",
"       </li>",
"       <li>",
"        Menzies SW, Ingvar C, Crotty KA, McCarthy WH. Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. Arch Dermatol 1996; 132:1178.",
"       </li>",
"       <li>",
"        Haenssle HA, Korpas B, Hansen-Hagge C, et al. Seven-point checklist for dermatoscopy: performance during 10 years of prospective surveillance of patients at increased melanoma risk. J Am Acad Dermatol 2010; 62:785.",
"       </li>",
"       <li>",
"        Argenziano G, Fabbrocini G, Carli P, et al. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998; 134:1563.",
"       </li>",
"       <li>",
"        Argenziano G, Catricala C, Ardigo M, et al. Seven-Point Checklist of Dermoscopy Revisited. Br J Dermatol 2010.",
"       </li>",
"       <li>",
"        Zalaudek I, Argenziano G, Soyer HP, et al. Three-point checklist of dermoscopy: an open internet study. Br J Dermatol 2006; 154:431.",
"       </li>",
"       <li>",
"        Argenziano G, Puig S, Zalaudek I, et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. J Clin Oncol 2006; 24:1877.",
"       </li>",
"       <li>",
"        Henning JS, Dusza SW, Wang SQ, et al. The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy. J Am Acad Dermatol 2007; 56:45.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35613=[""].join("\n");
var outline_f34_49_35613=null;
var title_f34_49_35614="Light chain amyloidosis survival by NT-proBNP response";
var content_f34_49_35614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Survival curves for patients with systemic light chain amyloidosis stratified by NT-proBNP response or progression at six months",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 398px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the international series of 816 patients from seven centers, staging cardiac biomarkers were available for 53 percent (432/816). Of these, 24 percent were stage 1 (both NT-proBNP p &le;332 ng/L and cardiac troponin T (cTnT) p &le;0.035 ng/mL or cTnI p &le;0.1 ng/mL), 52 percent stage 2 (NT-proBNP &gt;332 ng/L or cTnT &gt;0.035 ng/mL or cTnI &gt;0.1 ng/mL), and 24 percent stage 3 (both NT-proBNP &gt;332 ng/L and cTnT &gt;0.035 ng/mL or cTnI &gt;0.1 ng/mL). In these survival curves, results for 377 patients with baseline NT-proBNP greater than or equal to 650 ng/L are shown according to NT-proBNP response or progression at six months.",
"    <sup>",
"     [1]",
"    </sup>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Palladini G, Dispenzieri A, Gertz MA, et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood 2010; 116:1364a.",
"       </li>",
"      </ol>",
"      Reprinted by permission from Macmillan Publishers Ltd: Leukemia, Comenzo RL, Reece D, Palladini G, Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis, advance online publication, 15 May 2012 (DOI: 10.1038/leu.2012.100). Copyright &copy; 2012.",
"      <a href=\"file://www.nature.com/leu/index.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"       file://www.nature.com/leu/index.html",
"      </a>",
"      .",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35614=[""].join("\n");
var outline_f34_49_35614=null;
var title_f34_49_35615="Hormone resp hypophosphatemia";
var content_f34_49_35615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Hormonal response to hypophosphatemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Physiologic sequence of events following the stimulation of calcitriol formation by hypophosphatemia. The net effect is an increase in the plasma phosphate concentration with only a slight increase in the plasma calcium concentration. Both the latter change and the direct inhibitory effect of calcitriol contribute to the decline in PTH release in this setting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from DeLuca, H, Am J Med 1975; 58:39.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_49_35615=[""].join("\n");
var outline_f34_49_35615=null;
